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Abstract 
The use of targeted drug delivery has significantly improved the field of medicine in the 
last 30 years. At the same time, the field of DNA nanotechnology has allowed for the design 
nanoparticles with exact nanoscale precision. This thesis combines the two fields by using 
single-stranded DNA amphiphiles, a novel class of biomaterials, to create new targeted 
drug delivery vehicles. 
DNA aptamers are a sub-class of single stranded DNA molecules whose three-dimensional 
structure allows them to bind to one molecule with high affinity. ssDNA-amphiphile 
micelles were created from a ssDNA aptamer sequence to create a targeted ssDNA micelle 
for cancer therapies. These targeted micelles were shown to internalize only to cells 
expressing the aptamer target and release into the cytosol over 24 h. In vivo studies showed 
that although tumor accumulation of ssDNA-amphiphile micelles is independent of their 
targeting capability, internalization of the micelles requires the aptamer sequence. 
DNA-amphiphiles have also been shown to form nanotubes when in aqueous solution, 
dependent on the exact DNA sequence and lipid tail structure used. One ssDNA-
amphiphile that forms nanotubes was used for delivery to mouse glioblastoma cells. The 
nanotubes were shown to internalize to the glioblastoma cells, but not to healthy mouse 
astrocytes. When delivered directly to both hemispheres of the brains of mice with tumors 
in the right hemisphere, retention was observed only in the tumor hemisphere and not in 
the healthy hemisphere. This observation was conserved when the nanotubes were 
delivered systemically.  
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The nanotubes were then used for an initial in vitro chemotherapy experiment. When mixed 
with the chemotherapeutic doxorubicin, the nanotubes released little chemotherapeutic 
over the course of two weeks, with no significant change in the nanotube structure over 
this time. When delivered to mouse glioblastoma cells, the doxorubicin – nanotube mixture 
showed better cell toxicity compared to free doxorubicin. This is a promising result for 
chemotherapeutic delivery of the nanotubes. 
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1 Introduction 
The evolution of nanotechnology in the field of medicine has contributed greatly to the 
improved survivability and quality of life for many types of disease. Over the past thirty 
years, this field of medicine has grown extensively, with an industry estimated worth in 
2016 of 138.8 Billion USD and an estimated to worth of over 350 Billion USD by 2025.1 
The field of nanomedicine is centered around improving the efficacy of delivered drugs. 
This can be done by improving the percentage of drug that reaches certain regions of 
interest or by increasing the overall lifetime of the drug in the body.  
 Improvements in nanotechnology have led to the introduction of targeted drug delivery 
therapies, whereby unique regions of the body, such as tumors, can be specifically targeted 
based on the characteristics of the drug delivery vehicle. This increases the amount of drug 
delivered to the region of interest, while decreasing delivery to unintended regions. The 
enhanced permeability and retention (EPR) effect is a characteristic of many tumors that 
passively leads to higher accumulation of nanoparticles in tumors compared to healthy 
tissue.2 Active targeting can also be used by incorporating specific molecules into the drug 
delivery vehicle that bind to target molecules expressed only in the region of interest. This 
is commonly achieved by the incorporation of antibodies, using ligands for specific 
receptors, using pH-responsive materials, or using aptamers.3-5 The introduction of 
poly(ethylene glycol) (PEG) coatings in nanomedicine helped to significantly increase the 
circulation lifetime of liposomes, a self-assembled nanoparticle that can act as a drug 
carrier.6 These liposomes have come to be termed “stealth liposomes”, as they increase 
circulation lifetime by evading clearance by the body’s immune system. This approach has 
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been used by chemotherapeutics such as Doxil, a PEGylated liposomal form of 
doxorubicin, to increase the circulation time of the drug.7  
This thesis discusses the use of nanostructures composed of self-assembled single-stranded 
DNA (ssDNA)-amphiphiles and their use in targeted drug delivery applications. The use 
and characterization of ssDNA-amphiphiles is relatively new, but these molecules hold 
significant promise in the field of nanomedicine. In order to understand how ssDNA-
amphiphiles can be used in the field of nanomedicine, it is first important to understand 
amphiphilic molecules and their self-assembled structures, how nanoparticles in general 
can be targeted to certain regions of interest, such as cancer, and what types of therapeutic 
molecules are commonly delivered. This chapter will cover each of these topics while the 
remaining chapters of this thesis will discuss how ssDNA amphiphiles can be utilized as 
targeted delivery vehicles.   
1.1 Amphiphiles 
1.1.1 Amphiphile Structure 
The word amphiphile comes from the Greek amphi, meaning both, and philia, meaning 
love, together describing molecules that interact well with both water-based and oil-based 
solvents. Amphiphiles generally consist of a hydrophilic (water-loving) and lipophilic (fat-
loving) or hydrophobic (water-hating) portion as shown in Figure 1.1.   
Commonly, these regions of an amphiphile are referred to as the “headgroup”, for the 
hydrophilic region, and the “tail”, for the hydrophobic region, as many common 
amphiphile structures consist of a tail-like hydrocarbon chain and a bulky, sometimes 
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charged hydrophilic region that can be taken as a sphere. The unique structural 
characteristic of amphiphiles, molecules composed of both hydrophilic and hydrophobic 
regions, allows them to interact with each other and aggregate into larger, more complex 
structures. This process is driven by a complex set of interactions between the amphiphile 
molecules interacting with themselves and interacting with the surrounding solvents. The 
remainder of this thesis will only consider aqueous solutions for amphiphilic interactions, 
but the general forces that drive amphiphilic self-assembly can be interpreted for any type 
of solvent. 
 
Figure 1.1 Basic structure of an amphiphile, with the hydrophilic (water-loving) circular headgroup, and the 
hydrophobic (water-hating) tail. 
1.1.2 Driving Force for Self-Assembly and Packing Considerations 
The driving force for self-assembly of amphiphiles can be broken down into two main 
parts: interactions between the amphiphile and the solvent, and interactions between the 
amphiphile and other amphiphiles. The overall combination of these forces influences the 
size and shape of the resulting self-assembled structure; therefore, changing the strength of 
each of these interactions is essentially the same as controlling what types of structures 
each amphiphile will form. 
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The classical force driving the self-assembly of amphiphilic molecules is known as the 
“hydrophobic effect”. This interaction is driven by the hydrophobic regions of the 
amphiphile aggregating together to minimize contact with the solvent. Despite this 
seemingly simple attractive description of what appears to occur, this aggregation is 
actually the result of interactions between the amphiphile and the solvent molecules.8-10 If 
the hydrophobic region of the amphiphile is exposed to water, the surrounding water 
molecules have very low entropy, as they are forced into a specific conformation to solvate 
the tail. However, as the hydrophobic tails aggregate together, the water molecules are no 
longer trapped in a specific conformation, as there are no exposed tails to solvate. This 
leads to an overall increase in entropy of the system, which makes the aggregated 
amphiphile state the lowest energy state of the system.  
Interactions between individual amphiphiles include Van der Waals interactions, which 
describe the interactions between the electron clouds of atoms. These interactions can be 
attractive or repulsive in nature, and are often strong relative to other intermolecular 
forces.11 Electrostatic forces, commonly associated with the headgroup of the amphiphile, 
can directly affect self-assembly. Although these forces are typically repulsive, as 
individual amphiphiles of the same type will have the same charge on their headgroup, 
combining two different amphiphiles with oppositely charged headgroups can lead to 
attractive interactions.12 The strength of electrostatic interactions can be changed by 
adjusting environmental parameters such as the type of solvent, the pH of the solution, and 
the amount of dissolved electrolyte in solution.8, 13-17 Additionally, hydrogen bonds can 
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allow for significant interactions between amphiphile molecules, allowing for drastic 
changes in the types of self-assembled structures that are formed.18, 19  
The analysis of self-assembled structures formed from amphiphilic aggregation was 
pioneered in the 1970’s by Tanford and Isrealachvili. Tanford developed a mathematical 
formulation describing amphiphilic self-assembly based on the sum of two forces: 
repulsive forces between amphiphiles based on electrostatic and steric repulsion, and 
attractive forces dominated by the hydrophobic force.9, 10 From this analysis, Israelachvili 
developed the concept of the packing parameter of an amphiphile, a single parameter which 
is able to describe the self-assembled structure of a wide variety of amphiphiles.11  
The packing parameter considers three geometric parameters of the amphiphile to describe 
the shape of the amphiphile, and thereby the shape of the self-assembled structure when 
the amphiphile is close-packed in 3-dimensional space. The first parameter is the occupied 
surface area of a single amphiphile’s headgroup on the superstructure surface, called the 
optimal headgroup area, ao. The second parameter is the volume occupied by the tail of a 
single amphiphile, v. The third parameter is the length of the amphiphile’s hydrophobic 
tail, lc. The packing parameter, P, is then defined as v/(ao · lc). Another interpretation of this 
dimensionless parameter is the ratio of the effective area of the hydrophobic tail, as 
represented by v/lc, and the optimal headgroup area, ao. For simple amphiphiles, the value 
of the packing parameter defines the types of self-assembled structures that are formed, as 
shown by the cartoon in Figure 1.2.  
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Figure 1.2 A cartoon representation of the shape of different amphiphiles, the packing parameter associated 
with each shape, and the types of self-assembled structures those amphiphiles form. Reprinted with 
Permission from Zhang et al.20  
For values of the packing parameter less than 1/3, spherical micelles are formed; for values 
between 1/3 and 1/2, cylindrical micelles are formed; for values between 1/2 and 1, 
liposomes or vesicles are formed; for values approximately equal to 1, bilayers are formed. 
The basis for Israelachvili’s analysis was Tanford’s model of the energetic contributions 
driving self-assembly of the amphiphiles. Notably, Tanford created two simple linear 
equations that would describe the length of a fully extended hydrocarbon chain and the 
volume of that chain. When the length of the chain is greater than approximately eight 
carbons, the ratio of v/lc was approximately constant.10 Therefore, from Israelachvili’s 
analysis, the dominating factor that controls the packing parameter for this analysis is the 
optimal headgroup area, ao.  
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Figure 1.3 Schematic showing the change in self-assembled structure based on the size of the amphiphilic 
headgroup, as visualized by cryogenic transmission electron microscopy. Reprinted with permission from 
Chien et al.21 
A well-defined example of the role of the packing parameter and the effect of the optimal 
headgroup area can be seen in Figure 1.3.21  In the work by Chien et al., amphiphiles were 
formed from a hydrophobic tail coupled to a DNA brush layer. This created a large 
headgroup area that led to the assembly of spherical micelles. Through the addition of 
enzymes that degrade the DNA, the headgroup area was reduced. This changed the packing 
parameter and allowed for the assembly of cylindrical micelles. Upon the addition of a 
complementary DNA sequence (ln1) that bound to the DNA headgroup, the headgroup area 
increased, thereby reforming the spherical micelles expected for a small packing parameter. 
This could then be reversed back to the cylindrical micelles by removing the 
complementary DNA sequence (ln1) through the addition of a competing DNA sequence 
(ln2). Thus, the packing parameter analysis proposed by Israelachvili is a powerful tool in 
predicting aggregated amphiphile structures. 
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1.1.3 ssDNA-Amphiphile Self-Assembled Structures 
Much of the amphiphile literature focuses on the use of small molecule headgroups or 
oligopeptide headgroups. The Kokkoli research group has previously developed single-
stranded DNA (ssDNA)-amphiphiles that are composed of three main building blocks. The 
hydrophilic headgroup is composed of a ssDNA molecule instead of the typical small 
molecule or peptide. This ssDNA molecule can have any sequence of nucleotides and is 
usually between 10 and 40 nucleotides in length. The hydrophobic tail of the amphiphile 
is typically composed of two hydrocarbon chains. The third optional component of the 
amphiphile is a spacer region that acts to separate the ssDNA headgroup from the 
hydrophobic tail. The chemical nature of this spacer component can be changed as desired 
to increase the effective size of the hydrophilic headgroup or hydrophobic tail.  
Based on the packing parameter analysis for amphiphiles, it would be expected that these 
ssDNA-amphiphiles should form only spherical micelles, as they are composed of a bulky 
hydrophilic ssDNA headgroup that typically weighs between 4 and 15 kDa and they only 
have a small hydrocarbon tail that typically weighs less than 1 kDa. Indeed, cryogenic 
transmission electron microscopy (cryo-TEM) imaging shows that micelles are commonly 
formed from ssDNA-amphiphiles in aqueous solutions.22-24 However, it was also observed 
that some ssDNA-amphiphiles formed flat nanotapes, twisted nanotapes, helical nanotapes, 
and nanotubes,22-24 with the growth of nanotubes progressing through each of these 
structures over time.24   
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This alone is a surprising result, as the packing parameter analysis developed from Tanford 
and Israelachvili’s formulations suggest that these types of structures should not be 
observed. From the packing parameter analysis, the effective area of the hydrophilic 
headgroup should be the dominating parameter that controls the self-assembled structures 
that are formed. However, the definition of the headgroup area as the physical size of the 
headgroup leads to an incomplete analysis of the packing parameter, as this definition 
ignores thermodynamic considerations such as temperature, salt concentrations, pH, and 
intermolecular interactions. All of these thermodynamic considerations can affect the 
packing dynamics of the amphiphiles. It has been shown in the literature that headgroup 
interactions that are not accounted for by the packing parameter analysis can lead to self-
assembled structure that otherwise would not be predicted.18, 19 While interactions between 
amphiphilic headgroups should not be ignored, numerical analysis in the literature has also 
shown that the role of the hydrophobic tail should not be ignored as it is in Israelachvili’s 
analysis.25 Together, this indicates that the packing parameter can be used as a guide for 
what types of structures are likely to form, but correct conclusions can only be drawn from 
experimental observation. Indeed, the nanotape and nanotube structures observed by 
ssDNA-amphiphiles in the Kokkoli group are not unique to the literature, as these 
structures have been seen extensively in the peptide-amphiphile literature.26-31 However, 
to our knowledge, these are the first such structures observed from ssDNA-amphiphiles. 
1.1.4 Headgroup and Spacer Effects on Structure 
Previous work in the Kokkoli group has shown that both the sequence of the ssDNA 
headgroup and the type of spacer used between the headgroup and tail have an effect on 
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the self-assembled structures observed. A common secondary structure observed in the 
ssDNA headgroup of these amphiphiles is a g-quadruplex. G-quadruplexes are formed 
from guanine-rich sequences of DNA through the stacking of three or more g-tetrads, 
where four guanines interact through hydrogen bonds in a circular fashion. The canonical 
Watson-Crick face of a guanine is capable of hydrogen bonding with the Hoogsteen face 
of an adjacent guanine. A schematic of this interaction is shown in Figure 1.4. Work done 
by the Kokkoli group has demonstrated that the presence of g-quadruplexes in the ssDNA 
headgroup of ssDNA-amphiphiles is beneficial for the formation of the nanotape and 
nanotube structures, however they are not necessary for nanotape or nanotube formation.22-
24 Additionally, the use of a hydrocarbon chain as a spacer between the ssDNA headgroup 
and the dialkyl tail helps to promote nanotube development.22-24 
 
Figure 1.4 Left is a schematic of a g-tetrad, with hydrogen bonds between the Watson-Crick and Hoogsteen 
faces of adjacent guanines. Middle is an intramolecular parallel g-quadruplex. Right is an intramolecular anti-
parallel g-quadruplex.  
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G-quadruplexes have been shown to form from a single DNA strand that folds upon itself 
(as depicted in Figure 1.5), two DNA strands that interact together, or four individual DNA 
strands.32-35 G-quadruplexes can also be classified as parallel or anti-parallel based on the 
direction of the DNA strands that form the quadruplex. The differences between parallel 
and anti-parallel g-quadruplexes can be determined by the Circular Dichroism spectra of 
the molecule, where parallel structures have a strong positive peak between 258 and 265 
nm, and anti-parallel structures have a negative peak at 260 nm and a positive peak at 290 
nm.36, 37 This allows for the identification and characterization of g-quadruplexes formed 
from new, unique DNA sequences. 
1.2 Cancer Targeting 
Cancer is a unique tissue in the body as it is considered a disease, but is entirely made from 
the body’s own cells. Cancer is believed to have six to eight hallmark characteristics: 
“sustaining proliferative signaling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis, and activating invasion and 
metastasis,”38, 39 as well as “the reprogramming of energy metabolism, and evading the 
immune system.”39 Researchers have developed ideas and methods for targeting and killing 
cancer based on the framework of these hallmarks. Cancer targeting can be achieved 
through passive targeting and through active targeting. Passive targeting is commonly 
defined as delivery of the therapeutic agent to the tumor based entirely on the therapeutic 
physical characteristics and the environmental physical characteristics, with no specific 
interactions occurring between the delivered agent and its target.40 Active targeting is 
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commonly defined as delivery of the therapeutic agent to the tumor based on the attachment 
of specific ligands to the tumor tissue.40  
1.2.1 Passive Targeting and the Enhanced Permeation and Retention Effect 
Passive targeting of therapeutics to tumors is often described through the enhanced 
permeation and retention (EPR) effect. The EPR effect is the explanation for the 
observation that nanoparticles and macromolecules of a specific size tend to accumulate in 
tumor tissues more than healthy tissues when delivered systemically.2, 41, 42 One of the 
hallmarks of cancer is the induction of angiogenesis, whereby fast-growing tumor tissue 
needs access to many blood vessels to receive the nutrients to sustain rapid growth. During 
this growth, new blood vessels are often irregular in structure, which often leads to porous 
vessel walls compared to those found in healthy tissues. This porous structure allows 
nanoparticles and macromolecules to extravasate from the blood vessels and accumulate 
in the tumor tissue.  
Though the EPR effect can improve the delivery of therapeutic nanoparticles to the tumor 
tissue, there is a counterbalancing force that prevents accumulation: the clearance of 
nanoparticles from the bloodstream by the reticuloendothelial system (RES). It has been 
shown that the overall success of a passively-targeted therapeutic nanoparticle is directly 
related to its blood circulation lifetime.43 As the nanoparticle increases its circulation 
lifetime, there is a higher chance of passing through blood vessels adjacent to the tumor, 
which would allow for accumulation into the tumor via the EPR effect. Therefore, 
increasing the circulation lifetime of a drug will directly increase its efficacy when 
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passively targeted. The most common method of increasing circulation lifetime of a 
nanoparticle is by adding poly(ethylene glycol) (PEG) to the exterior.6, 44-46 The addition 
of a PEG outer layer helps to create steric repulsion between the nanoparticle and the 
macrophages that would act to clear the nanoparticles from the bloodstream. The use of 
nanoparticles that fall within the specific size range of 10 nm and 100 nm leads to the best 
overall utilization of the EPR effect,47-51 as clearance by the kidney occurs for nanoparticles 
smaller than 10 nm51, 52 and clearance by the liver occurs for nanoparticles larger than 100 
nm.51  
1.2.2 Direct Targeting 
Direct targeting of tumors involves the incorporation or direct use of ligands that are 
specific to molecules expressed by the tumor tissue. Many ligands used in tumor targeting 
are specific to molecules associated with one of the hallmarks of cancer. For example, 
vascular endothelial growth factor (VEGF) is an excreted protein that induces the 
formation of new blood vessels.53-55 As tumors are constantly creating new blood vessels 
to sustain their fast growth rate, VEGF is widely expressed in the tumor tissue. The benefit 
of targeting a protein involved in the hallmarks of cancer, such as VEGF, is that the protein 
is likely to be present in the tumor tissue, allowing for binding of the nanoparticle.56, 57 
However, a more general goal is to target molecules that are expressed in much higher 
amounts in the tumor tissue as compared to the healthy tissue, with the ultimate goal of 
finding molecular targets that are expressed only in the tumor tissue. Doing so would help 
to prevent off-targeting that can lead to side effects when delivering toxic therapeutics 
designed to kill tumor tissue. As an example of potential healthy tissue off-targeting, VEGF 
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is also known to be expressed in embryonic tissues or areas of the body that require new 
blood vessels after injury.53 Therefore, the use of VEGF-targeting therapeutics has led to 
some adverse effects when used as a cancer targeting therapy.58  
Several classes of ligands have been utilized to target tumors in the literature. Antibodies 
are the only class of macromolecules that are currently approved by the FDA for targeted 
therapies in clinical use. Antibodies are the immune system’s natural method of targeting 
specific molecules and antibodies are typically specific to one antigen. Due to the 
specificity offered by antibodies, several therapies have been developed utilizing 
antibodies over the last 15 years.59-64 The basis for an antibody’s specific binding is a short 
peptide sequence known as the complementarity determining region, and generally 
consists only of a few amino acids of the entire antibody structure. The three-dimensional 
conformation as well as the actual sequence of the amino acids is what determines the 
specificity of the antibody. Therefore, it is easy to imagine that specific binding can be 
observed for any short sequence oligopeptide sequence, even if the oligopeptide is not 
attached to the large carriers like the antibody heavy and light chains. Many small-molecule 
peptides have been developed that are specific to certain tumor targets,65-67 and research is 
ongoing to utilize these small molecules as targeting moieties for therapeutic nanoparticles.  
The specific binding to a target of interest due to chemical sequence and three-dimensional 
conformation is not a unique property of amino acids. DNA aptamers are nucleic acids that 
have the same binding properties as amino acids based on the chemical sequence, 
secondary structure, and tertiary structure. DNA aptamers are often selected through a 
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process known as the systematic evolution of ligands by exponential enrichment (SELEX), 
whereby a large library of unique oligonucleotide sequences is exposed to the desired target 
and enriched over many cycles to identify only the few sequences that bind strongly to the 
target.68, 69 This process allows for the identification of DNA aptamers that are capable of 
binding to any desired target. The Kokkoli group has previously used this process to 
identify the FKN-S2 aptamer,70 which targets the chemokine fractalkine. 
1.2.3 Effect of Shape on Targeting 
The effect of nanoparticle shape must be considered when designing targeted drug delivery 
vehicles. Spherical nanoparticles are often the most utilized nanoparticles as they are 
readily formed from a wide variety of materials and can be synthesized in many different 
sizes. Examples include spherical micelles from amphiphilic molecules, liposomes from 
amphiphilic molecules or natural origins such as vesicles, and metallic nanoparticles such 
as gold nanoparticles.  
In an article written by Kolhar et al., it was shown that antibody-coated rod-shaped 
nanoparticles are capable of internalizing to a much higher degree than spherical 
nanoparticles with the same antibody coating and of similar volume.71 This effect was 
observed both in vitro in microfluidic devices simulating the vasculature, as well as in vivo 
when displaying antibodies targeted against the lung and the brain. The authors suggested 
that the high aspect ratio of the rod-shaped nanoparticles allowed a larger percentage of 
their surface area to come into contact with the target, thereby allowing a larger fraction of 
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the antibody coating to bind with the target. Additionally, shear alignment of elongated 
particles in fluid flow likely helps to ensure a large contact area with the vessel wall. 
In addition to the increased binding available for high aspect ratio molecules, different 
types of cells have been shown to have different preferences for nanoparticle 
internalization.72 Agarwal et al. demonstrated that after controlling for volume, charge, and 
material composition, mammalian cells preferentially internalize nanoparticles of different 
shapes. It was shown that epithelial cells and immune cells preferentially internalize disc-
shaped nanoparticles as compared to rod-shaped nanoparticles. Additionally, the 
internalization pathways vary between cell types. An example of preferential 
internalization based on shape and cell type can be seen in Figure 1.5.  
 
Figure 1.5. Differences in nanoparticle uptake as a function of cell type, nanoparticle size, and nanoparticle 
aspect ratio. Reprinted with permission from Agarwal et al.72  
The authors proposed in this work that the shape-dependent internalization is dependent on 
the contact area between the nanoparticle and the cell, the energy required to deform the 
cell membrane, and the localized concentration of nanoparticles on the cell membrane.72 It 
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is therefore difficult to predict how nanoparticles will interact with various cell types a 
priori, and experiments to evaluate cellular interaction and internalization should be 
performed for new types of nanoparticles. 
1.3 Chemotherapeutics 
1.3.1 Chemotherapeutic Methods of Action 
The term “chemotherapeutic” has come to describe small molecule drugs that non-
specifically internalize to cells and prevent mitosis. A general descriptor of cancer is that 
it reproduces uncontrollably; therefore, preventing mitosis is one of the most effective ways 
of stopping the spread of cancer cells. Many classes of chemotherapeutics exist that act to 
prevent mitosis.73   
Alkylating agents were one of the first classes of chemotherapeutics to be used clinically,74  
and act by covalently binding to the DNA strand, which can lead to DNA strand breakage 
during DNA replication or transcription.73, 75 Anthracyclines such as doxorubicin, 
daunorubicin, and their derivatives are some of the most commonly used and most effective 
chemotherapeutics.76, 77 These molecules have a number of cytotoxic mechanisms, which 
include intercalation into nucleic DNA strands to prevent DNA replication, the generation 
of free radicals, and the inhibition of topoisomerase. Antimicrotubule agents, such as 
paclitaxel and docetaxel, act by inhibiting the function of microtubules during the cell 
division process.78 Paclitaxel specifically stabilizes the microtubule, preventing its 
degradation during mitosis, eventually leading to cell death.  
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The common theme among all chemotherapeutics is that rapidly dividing cells are affected 
by the chemotherapeutic more than slowly dividing cells, as a smaller fraction of slowly 
dividing cells are undergoing mitosis while the chemotherapeutic is in blood circulation. 
However, healthy cells that divide quickly are indistinguishable from cancer cells during 
treatment, as the chemotherapeutics themselves are not targeted. This is the basis for many 
of the side effects observed after chemotherapy regimens. The death of fast-dividing cells, 
such as the bone marrow, the stomach lining, and hair follicles, lead to common 
chemotherapy side effects: weakened immune system, nausea and vomiting, and loss of 
hair, respectively. These are among the top-rated side effects in terms of severity, as 
reported by chemotherapy patients in the clinic.79 It is therefore important to develop 
targeted delivery mechanisms to help alleviate the side effects associated with 
chemotherapeutic regimens.  
A wide variety of chemotherapeutics have been developed for clinical use. Many 
chemotherapeutics are simple formulations of the small-molecule drugs that create the 
therapeutic effect. However, derivatives of these drugs are also utilized in the clinic, where 
some aspect of drug delivery, such as blood circulation lifetime, is improved over the basic 
formulation. Over 100 chemotherapeutics are used on their own or in combination with 
other chemotherapeutics to treat cancer. Therefore, an exhaustive list of clinically used 
treatments is beyond the scope of this thesis. However, several reviews of clinical research 
give an overview of treatments used for different types of cancer.80-84 
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1.3.2 Doxorubicin 
Doxorubicin one of the most widely used chemotherapeutics,76, 77 having first been 
approved for use in the United States in the 1970’s. It is currently on the list of the World 
Health Organization’s “Essential Medicines” and is specifically cited by the World Health 
Organization as a cytotoxic medicine for the treatment of five types of lymphoma, three 
types of sarcoma, and both early-stage and metastatic breast cancer.85 However, 
doxorubicin is also used to treat bladder, stomach, lung, ovarian, and thyroid cancers. 
Doxorubicin was first isolated from the bacteria Streptomyces peucetius along with 
daunorubicin, a chemotherapeutic that differs from doxorubicin by the lack of a single 
hydroxyl group.86  
Doxorubicin, and other similar anthracyclines, interact with DNA by intercalating into the 
DNA structure.86-89 This intercalation is known to prevent the action of DNA and RNA 
polymerase, which leads to the cessation of DNA replication and RNA transcription. 
Doxorubicin is also capable of stabilizing topoisomerases during the coiling and un-coiling 
process of the nuclear DNA. This stabilization of the topoisomerase system prevents re-
sealing of the DNA helix after it has been broken for coiling or uncoiling, and eventually 
leads to cell death.90 Additionally, it has been shown that doxorubicin can lead to the 
increased production of reactive oxygen species such as hydroxyl radicals, which can lead 
to further DNA damage and inhibition of macromolecule production.91 There is evidence 
to suggest that each mechanism of doxorubicin cytotoxicity occurs at different doxorubicin 
concentrations, with sub-micromolar concentrations leading to interference of DNA 
replication and RNA transcription, with concentrations between 2 and 4 µM leading to free 
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radical production, and concentrations near peak plasma concentration immediately after 
injection leading to topoisomerase stabilization and inhibition.92 
Doxorubicin is available in several formulations for different clinical applications. The 
original formulation consisted of solely doxorubicin delivered intravenously. This 
formulation is sold under the trade name Adriamycin and is commonly delivered as part of 
a chemotherapeutic cocktail with other chemotherapeutics such as paclitaxel, or its 
synthetic derivative docetaxel. In 2005, a PEGylated liposomal form of doxorubicin was 
approved by the FDA for use in the United States.7 The PEG coating of the liposomal form 
helps to increase the of blood circulation lifetime of doxorubicin, thereby increasing its 
efficacy through the EPR effect. The incorporation of targeting molecules into the delivery 
mechanisms of doxorubicin should lead to significant increase in efficacy and decrease in 
side-effects. 
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2 Aptamer Micelles Targeting Fractalkine-Expressing 
Cancer Cells In Vitro and In Vivo 
* Adapted with permission from Harris, Pearce et al. Copyright 2017 Elsevier.93  
2.1  Summary 
In this work we hypothesized that the chemokine fractalkine can serve as a cancer 
molecular target. We engineered aptamer micelles functionalized with an outer PEG 
corona and investigated the extent and efficacy of using them as a targeting tool against 
fractalkine-expressing colon adenocarcinoma cells. In vitro cell binding results showed 
that aptamer micelles bound and internalized to fractalkine-expressing cancer cells with 
the majority of the micelles found free in the cytoplasm. Minimal surface binding was 
observed by healthy cells. Even though partial PEGylation did not prevent serum 
adsorption, micelles were highly resistant to endonuclease and exonuclease degradation. 
In vivo biodistribution studies and confocal studies demonstrated that even though both 
aptamer and control micelles showed tumor accumulation, only the aptamer micelles 
internalized into fractalkine-expressing cancer cells, thus demonstrating the potential of the 
approach and showing that fractalkine may serve as a specific target for nanoparticle 
delivery to cancer cells. 
2.2 Introduction 
Nanomedicine has developed into a promising field for the delivery of therapeutics to 
tumors, but with several obstacles that need to be resolved. Tumor targeting in general is 
aided by the EPR effect,2 whereby macromolecules show preferential accumulation in 
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tumor tissue compared to healthy tissue. The size and shape of nanoparticles used for in 
vivo delivery can strongly affect the biodistribution and cellular uptake of the 
nanoparticles.51, 94-98 Additionally, the charge of the nanoparticles,99 types of targets used 
such as folate receptor, epidermal growth factor receptor (EGFR) or integrins,100 and the 
extent of functionalization with polymeric materials such as PEG101 can strongly affect the 
ability of the nanoparticle to enter the tumor tissue and internalize into the tumor cells. The 
extent of internalization must be considered when delivering therapeutics that do not 
readily cross the cell membrane, such as microRNA (µRNA) or small interfering RNA 
(siRNA) therapeutics.  
ssDNA or RNA aptamers are a class of oligonucleotides that demonstrate high binding 
affinity for specific target molecules. Aptamers have been used to decorate different 
nanoparticles such as gold and iron oxide nanoparticles, carbon nanotubes, liposomes, 
micelles, and polymeric nanoparticles in order to provide targeting capabilities to these 
nanoparticles.102 A SELEX process was used to develop a 40 nucleotide (nt) guanine-rich 
ssDNA aptamer, FKN-S2,103 that targets a novel chemokine, fractalkine, with high affinity 
(Kd = 3.4 ± 0.7 nM of the free aptamer for fractalkine) and specificity, binding to the 
chemokine domain of fractalkine. Fractalkine, also known as CX3CL1,104 and one other 
chemokine, CXCL16,105 are the only chemokines that exist in two active forms, membrane-
bound and soluble. The soluble form is produced by cleavage of membrane-bound 
fractalkine near the cell membrane by the metalloproteinases ADAM10 and ADAM17, and 
is a chemoattractant for monocytes, natural killer cells and T-cells.106, 107 The membrane-
bound fractalkine captures CX3CR1 (fractalkine receptor)-expressing leukocytes via 
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integrin-independent binding,108 and has been shown to actively cycle between the plasma 
membrane and an internal, moderately acidic, vesicular pool.109 The chemokine domain of 
fractalkine sits on a glycosylated mucin-like stalk whose role is to extend the chemokine 
domain away from the cell membrane to decrease steric hindrance to binding.110  
Fractalkine is involved in several inflammatory disorders and the pathogenesis of different 
types of cancer.111 Constitutive expression of fractalkine on healthy organs is low or absent, 
while overexpression is seen under inflammation or cancer. For example, fractalkine was 
either not expressed, or a negligible diffuse expression was observed on normal human 
kidneys, while fractalkine was highly expressed in patients with renal inflammation or 
renal allograft rejection.112, 113 Fractalkine was absent in normal coronaries but present in 
several patients with coronary artery inflammatory disease.114 In patients with colorectal 
cancer, fractalkine was detectable to significantly higher extents than in healthy mucosa.115 
Similarly, normal human livers showed low levels of fractalkine, while increased 
expression was detected in patients with hepatitis.116 
Protein overexpression on cancer cells is a desirable feature for targeting. EGFR, for 
example, is expressed on healthy organs such as skin, liver, head, neck and gastrointestinal 
tract, and is overexpressed on different cancerous tissues, where the percentage of tumors 
that overexpress EGFR vary by tumor type.117, 118 Fractalkine’s overexpression in different 
diseases, and its ability to internalize, are two features that may make fractalkine a 
promising target for the delivery of therapeutics, as incorporation of fractalkine-targeting 
epitopes may allow both targeting and internalization of nanoparticles in a specific manner. 
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Even though a CX3CR1 antagonist has been developed  (a small-molecule called 
AZD8797),119 and shown to have efficacy in a rat model for multiple sclerosis,120 this is 
the first demonstration of a ssDNA aptamer, or any other ligand being used to target 
fractalkine, for in vitro and in vivo delivery of nanoparticles to fractalkine-expressing 
cancer cells.  
We have previously developed FKN-S2 aptamer-amphiphiles by conjugating a C16 dialkyl 
tail to the FKN-S2 aptamer.121 These aptamer-amphiphiles self-assembled in aqueous 
solution into micelles and nanotapes (flat bilayer structures that are often twisted) 
depending on the spacer used between the dialkyl tail and FKN-S2. The binding affinity of 
the aptamer was found to be affected by the addition of the tail, the orientation of the 
aptamer and type of spacer used.121 Conjugation of FKN-S2 at its 3’-end to a C16 dialkyl 
tail with a ten thymine oligonucleotide spacer (T10 spacer-dialkyl tail) showed the highest 
binding affinity of different FKN-S2-amphiphiles for fractalkine, although other spacers, 
such as short PEG, were also investigated.121 The 40nt FKN-S2 aptamer with the T10 spacer 
at its 3’-end, conjugated to a (C16)2 tail, self-assembled into micelles and will henceforth 
be referred to as FKN-S2-T10 aptamer-amphiphile.  
In this work, we show the ability for small self-assembled PEGylated micelles composed 
of FKN-S2-T10 aptamer-amphiphiles to specifically target and internalize into cancer cells 
that express fractalkine. In previous studies the aptamer extended outside the PEG corona 
of a polymeric nanoparticle,122 gold nanoparticle,123 or micelle,124 for example. This 
exposed the aptamer to nucleases and rapid enzymatic cleavage,123 and was shown to 
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compromise the antifouling properties of PEG at increased aptamer surface densities.122 In 
this study we took a different approach where PEG5000 was attached at the 5’-end of the 
aptamer, thus providing an outer PEG corona to the aptamer micelle.  
In vitro uptake experiments investigated the binding and internalization of the FKN-S2-T10 
micelles (PEGylated or not) by mouse colon adenocarcinoma MCA-38 cells transfected to 
expressing human fractalkine (MCA-38.FKN)121 and by control healthy human BJ 
fibroblasts. Binding and internalization of PEGylated FKN-S2-T10 micelles to control 
human colonic epithelial cells (HCoEpiC) was also examined. PEGylated FKN-S2-T10 and 
control micelles (formed by a random ssDNA-amphiphile with no guanines) were further 
investigated in vivo and therefore, their stability to serum and nucleases was examined.  In 
vivo experiments using a subcutaneous MCA-38.FKN tumor model evaluated 
biodistribution of the micelles overtime via micro positron emission tomography 
(µPET)/computerized tomography (CT). Ex vivo biodistribution studies were also 
performed. Confocal microscopy of the tumors investigated cell internalization of the 
PEGylated FKN-S2-T10 and control micelles by the fractalkine-expressing cancer cells. As 
a proof of concept, we demonstrated in this study that fractalkine can be used as targeting 
molecule both in vitro and in vivo and that even though PEGylated micelles can extravasate 
into the tumor independent of the ssDNA used to form the micells, the FKN-S2-T10 
aptamer is required for cell internalization by the fractalkine-expressing cancer cells. 
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2.3 Methods 
2.3.1 Materials 
All materials were purchased from Sigma-Aldrich (St. Louis, MO) and used without 
further purification or modification unless otherwise stated. Buffers include high 
performance liquid chromatography (HPLC) buffer A (100 mM hexafluoroisopropanol 
and 15 mM triethylamine in water), HPLC buffer B (100 mM hexafluoroisopropanol and 
15 mM triethylamine in methanol), TEAA buffer (50% molar basis triethylamine, 50% 
molar basis glacial acetic acid, pH = 7.0), Cu-TBTA (10 mM Copper (II)-Tris[(1-benzyl-
1H-1,2,3-triazol-4-yl)methyl]amine in 55% dimethyl sulfoxide (DMSO), 45% water), 1X 
phosphate buffered saline (PBS) (137 mM sodium chloride, 2.7 mM potassium chloride, 
10 mM disodium phosphate, 1.8 mM monopotassium phosphate in water), and 1X TBST 
(tris-buffered saline 20X (1 M) with tween 20 (BioLegend, San Diego, CA), diluted to 1X 
with distilled water, pH adjusted to 7.6 with HCl). 
2.3.2 Synthesis of ssDNA-Amphiphiles 
ssDNA sequences were purchased from Integrated DNA Technologies (Coralville, IA) 
with a 3’ amino-modifier for conjugation to the hydrophobic tail. The 5’ end was either 
unmodified or was ordered with a fluorophore (HEX 538(ex)/555(em) nm, Cy5 
648(ex)/668(em) nm, FAM 495(ex)/520(em)), or alkyne group for further modification. 
The FKN-S2 aptamer with T10 spacer (FKN-S2-T10: 5’-GGGGT GGGTG GGGGG 
CACGT GTGGG GGCGG CCAGG GTGCT TTTTT TTTTT-AmMo-3’) and control, 
random sequence containing no guanines, with T10 spacer (5’-TTCTA TTCTC ACATT 
TCATC TATTA AACCA CCAAT TAATT TTTTT TTTTT-AmMo-3’) were used in this 
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study. ssDNA was precipitated in water using 100 mM cetyl trimethylammonium bromide 
(CTAB) followed by resuspension in a 90%/10% (v/v) mixture of dimethylformamide 
(DMF) and DMSO at 500 µM. C16 dialkyl tails, synthesized as described elsewhere,121 
were added in 10X molar excess and reacted overnight at 60 °C. The solution was 
concentrated by drying under air stream until approximately 100 µL in volume. The ssDNA 
was precipitated by an ethanol precipitation, where 900 µL of ethanol were added followed 
by 30 µL of 3 M sodium acetate in water and 270 µL of water and placed in a -20 °C freezer 
for a minimum of 2 h. The precipitate was centrifuged, rehydrated with 800 µL of water 
and filtered through a 0.45 µm PES filter. The filtered ssDNA-amphiphiles were then 
separated from unreacted ssDNA using HPLC with HPLC buffer A and HPLC buffer B 
over 30 min. ssDNA-amphiphiles were then dried to approximately 1 mL, precipitated via 
ethanol precipitation to remove HPLC buffer components, and rehydrated at 500 µM in 
water for storage at -20 °C.  
2.3.3 Alkyne DOTA-Thiol Reaction 
ssDNA-amphiphiles with a 5’ alkyne modification were mixed with 10 molar equivalents 
of 1,4,7,10-tetraazacyclododecane-1,4,7,-tris(acetic acid)-10-(2-thioethyl)acetamide 
(DOTA-thiol) and one tenth molar equivalents of 2-hydroxy-2-methylpropiophenone 
photoinitiator in water. The solution was degassed under vacuum for 15 min and stirred 
under UV light for 2 h. The solution was dialyzed overnight using a Tube-O-DIALYZER 
Medi 1K MWCO dialysis membrane (G-Biosciences, St. Louis, MO). DOTA-labeled 
ssDNA-amphiphiles were then concentrated to 500 µM by drying under an airstream. 
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2.3.4 PEG Click Reaction 
ssDNA-amphiphiles with a 5’ alkyne modification were mixed in 50% water and 50% 
DMSO to a final concentration of 100 µM. TEAA buffer was added to a concentration of 
200 mM, Cu-TBTA buffer was added to a concentration of 1 mM, ascorbic acid was added 
to a concentration of 2 mM, and PEG5000-azide was added in 5 times molar excess of the 
ssDNA-amphiphiles. The solution was mixed and left overnight in the dark at room 
temperature, followed by an ethanol precipitation to remove excess buffer components. 
The PEGylated ssDNA-amphiphiles were rehydrated at 500 µM in water for storage at -20 
°C.  
2.3.5 Liquid Chromatography-Mass Spectroscopy (LC-MS) 
ssDNA-amphiphiles were analyzed using an Agilent 1100 LC MSD Model G1946 Mass 
Spectrometer at the University of Minnesota Masonic Cancer Center. ssDNA-amphiphiles 
at 500 µM were injected with 4 µL of volume onto a 300 µm C3 column with a 20-min 
gradient between 15 mM ammonium acetate in water and acetonitrile. The eluent of the 
chromatography column was sent to the mass spectrometer in order to determine the mass 
of the ssDNA-amphiphiles. 
2.3.6 Proton Nuclear Magnetic Resonance (1H NMR) 
1H NMR spectra were recorded on a Bruker 850 MHz spectrometer at the University of 
Minnesota NMR Center with 98% H2O/2% DMSO or 98% H2O/2% D2O at room 
temperature. 
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2.3.7 Micelle Preparation 
Micelle samples were prepared by heating a solution of different ssDNA-amphipiles at the 
desired ratios to 90 °C for 15 min and cooling to room temperature. Heating was done to 
induce disassembly of the amphiphiles24 and allow for formation of micelles composed of 
all different amphiphiles in the solution upon cooling.  
2.3.8 Dynamic Light Scattering (DLS) and Zeta Potential 
DLS and zeta potential measurements were made using a Brookhaven ZetaPALS Particle 
Analyzer. 250 µM ssDNA-amphiphile solutions were diluted to ~20 µM with 1X PBS and 
transferred to a 1.0 cm path length cuvette for data collection. For each micelle sample 
three independent DLS and zeta potential measurements were performed (n=3), each 
consisting of ten 1-min runs.  
2.3.9 Cyrogenic Transmission Electron Microscopy (Cryo-TEM) 
Lacey Formvar/Carbon 200 mesh copper grids were purchased from Ted Pella (Redding, 
CA) and glow-discharged for 1 min to make the grids more hydrophilic. 4.5 µL of 400 µM 
ssDNA-amphiphiles in 1X PBS were deposited onto the grid and vitrified in liquid ethane 
by Vitrobot (Vitrobot parameters: 4.5 sec blot time, 3 sec wait time, 3 sec relax time, 0 
offset, 95% humidity). The grids were kept under liquid nitrogen and transferred to a 
Tecnai G2 Spirit TWIN 20-120 kV/LaB6 TEM operated at an accelerating voltage of 120 
kV and an Eagle 2k CCD camera at the University of Minnesota Characterization Facility. 
Size analysis of 25 micelles from each formulation was performed using ImageJ. 
30 
 
2.3.10 Circular Dichroism (CD) 
250 µM solutions of ssDNA-amphiphile were diluted to 5 µM with 1X PBS and transferred 
to a 1.0 cm path length cuvette. CD spectra from 320-200 nm were collected using a Jasco 
J-815 spectrapolarimeter at the University of Minnesota Biophysical Technology Center, 
using a read speed of 50 nm min-1 in 1 nm steps. Three accumulations per amphiphile 
solution were recorded with the background spectrum of 1X PBS automatically subtracted. 
The accumulations were averaged and the raw ellipticity values were converted to molar 
ellipticity.  
2.3.11 Cell Culture 
MCA-38.FKN cells121 or BJ fibroblasts  (American Type Culture Collection, Manassas, 
VA) were cultured at 37 °C and 5% CO2 using Dulbecco’s Modified Eagle Medium 
(DMEM) (Thermo Fisher Scientific, Rockford, IL) supplemented with 10% (v/v) fetal 
bovine serum (FBS) (Thermo Fisher Scientific, Rockford, IL). Human colonic epithelial 
cells (HCoEpiC) (ScienCell Research Laboratories, Carlsbad, CA) were cultured at 37 °C 
and 5% CO2 using colonic epithelial cell medium supplemented with 100 units/mL 
penicillin, 0.1 mg/mL streptomycin, and 5 mL of colonic epithelial cell growth supplement 
(ScienCell Research Laboratories, Carlsbad, CA). Cells were passaged when they reached 
80% confluence by treatment with TrypLE Express cell dissociation agent (Thermo Fisher 
Scientific, Rockford, IL).   
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2.3.12 Fractalkine Expression via Flow Cytometry 
Fractalkine expression of MCA-38.FKN cells, BJ fibroblasts, and HCoEpiC was assessed 
by flow cytometry. 2x105 MCA-38.FKN cells and 1x105 BJ fibroblasts were each 
suspended in 200 µL of binding buffer consisting of 1X PBS supplemented with 1% (w/v) 
bovine serum albumin (PBS/BSA) and 5 µg/mL of anti-fractalkine antibody (AF365, R&D 
Systems, Minneapolis, MN) or an isotype control (02-6202, Thermo Fisher Scientific, 
Rockford, IL) were added. 2x104 HCoEpiC were suspended in 200 µL of PBS/BSA with 
2 µg/mL of anti-fractalkine antibody or the isotype control. After incubating for 30 min at 
4 °C, the cells were centrifuged, washed with PBS/BSA and suspended in 200 µL of 
PBS/BSA with 5 µg/mL (2 µg/mL were used for HCoEpiC) of a fluorescently labeled 
secondary antibody (NL002, R&D Systems, Minneapolis, MN). The cells were incubated 
with the secondary antibody for 30 min at 4 °C, washed twice with PBS/BSA, and assessed 
for fractalkine expression by flow cytometry (BD Accuri C6, University Flow Cytometry 
Resource, University of Minnesota).  
2.3.13 Micelle Binding and Internalization via Flow Cytometry 
Micelle samples containing 10 mol% HEX-labeled FKN-S2-T10 aptamer-amphiphiles and 
different concentrations of  PEGylated FKN-S2-T10 aptamer-amphiphiles and FKN-S2-T10 
aptamer-amphiphiles were prepared at 250 µM in 1X PBS. 25,000 MCA-38.FKN cells, or 
10,000 BJ fibroblasts were added to a 24-well plate and allowed to attach and proliferate 
for 24 h. After 24 h, fresh media and the micelle solutions were added to the cells at a final 
amphiphile concentration of 12.5 µM for each micelle sample. After an additional 24 h at 
37 °C the micelle solution was removed, the cells were detached from the plate, washed 
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with PBS, and analyzed with an Accuri C6 flow cytometer to assess the amount of cell 
fluorescence. The raw fluorescence data were scaled to the cell surface area of the MCA-
38.FKN or BJ fibroblasts to account for the substantial difference in cell size. The average 
surface area of 100 cells was calculated using ImageJ as 1,191 µm2 for the MCA-38.FKN 
cells and 5,409 µm2 for the BJ fibroblasts. Three independent experiments were conducted 
and the data analyzed for statistical significance between each micelle sample using a two-
way ANOVA with Tukey’s HSD post-hoc test. PEGylated FKN-S2-T10 micelles were also 
delivered to 25,000 MCA-38.FKN cells and 25,000 HCoEpiC for 24 h at 37 °C following 
the above protocol. MCA-38.FKN and HCoEpiC were compared using fluorescence 
values. Three independent experiments were performed and statistical significance was 
evaluated by student’s t-test analysis. 
2.3.14 Micelle blocking with FKN-S2-T10 free aptamer via flow cytometry 
Micelles containing 20 mol% HEX-labeled FKN-S2-T10 aptamer-amphiphiles, 40 mol% 
PEGylated FKN-S2-T10 aptamer-amphiphiles and 40 mol% FKN-S2-T10 aptamer-
amphiphiles were prepared at 250 µM in 1X PBS, while free FKN-S2-T10 aptamer (5’-
GGGGT GGGTG GGGGG CACGT GTGGG GGCGG CCAGG GTGCT TTTTTTTTTT-
3’) was prepared at 1 mM in 1X PBS. 100,000 MCA-38.FKN cells were suspended in vials 
with 1 mL of 1X PBS. 150 µL of 1X PBS (unblocked sample), or 150 µL free FKN-S2-
T10 aptamer (blocked sample) were added to the cell vials and incubated at 4 °C for 1 h. 6 
µL of micelle solution were added to the cell vials and incubated for an additional 1 h at 4 
°C. Cells were washed twice with 1X PBS, resuspended in 1X PBS and measured for 
fluorescence with an Accuri C6 flow cytometer. 
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2.3.15 Micelle Binding and Internalization via Confocal Microscopy 
Micelles containing 10 mol% Cy5-labeled FKN-S2 aptamer-amphiphiles, 45 mol% 
PEGylated FKN-S2-T10 aptamer-amphiphiles and 45 mol% FKN-S2-T10 aptamer-
amphiphiles were prepared at 250 µM in 1X PBS. 20,000 MCA-38.FKN, HCoEpiC, or BJ 
fibroblast cells were deposited onto glass coverslips contained within wells of a 24-well 
plate and allowed to attach and proliferate for 24 h. After 24 h, 25 µL of the micelle solution 
was added to the cells, bringing the final amphiphile concentration to 12.5 µM. 24 h after 
the micelles were added, cells were fixed with 4% paraformaldehyde and their nuclei and 
membranes simultaneously stained for 10 min with Hoescht 33342 (Thermo Fisher 
Scientific, Rockford, IL) at 0.92 µg/mL for the nucleus and Wheat Germ Agglutinin 
AlexaFluor594 (Thermo Fisher Scientific, Rockford, IL) at 5.0 µg/mL for the membrane.   
For the organelle staining and colocalization study, after MCA-38.FKN cells proliferated 
for 24 h, 25 µL of the micelle solution and 10 µL of CellLight Early Endosomes-GFP 
(Thermo Fisher Scientific, Rockford, IL) were added to the cells, bringing the final 
amphiphile concentration to 12.5 µM. Lysosomes were stained using Lysotracker Red 
(Thermo Fisher Scientific, Rockford, IL) by adding 5 µL of a 20 µM Lysotracker Red 
solution to the cells (final concentration: 200 nM) 2 h prior the 24 h experimental end-
point. 24 h after the micelles were added, cells were fixed with 4% paraformaldehyde and 
their nuclei stained with Hoescht 33342 at a concentration of 0.92 µg/mL for 10 min.  
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Cells were mounted onto glass slides using Prolong Gold and imaged with an Olympus 
FluoView FV1000 BX2 Upright Confocal microscope (University Imaging Centers, 
University of Minnesota).  
2.3.16 Micelle Serum Stability via Gel Electrophoresis 
Three different micelle formulations were investigated for stability after exposure to serum: 
FKN-S2-T10 micelles, PEGylated FKN-S2-T10 micelles, and PEGylated control micelles. 
All micelles contained 20 mol% HEX-labeled ssDNA-amphiphiles and were prepared at 
250 µM in water. Micelles were mixed into three separate conditions using 2.5 µL of 
micelles and 47.5 µL of solution, for 50 µL total mixture: 1X PBS as a control, 10% (v/v) 
FBS in water to mimic in vitro conditions, and 90% (v/v) FBS in water to mimic in vivo 
conditions. Micelle solutions were incubated at 37 °C for 24 h and were run on 2% agarose 
gels (2% agarose in 1X TAE buffer) at 120V for 35 min, and imaged using a ChemiDoc 
MP Imaging System (Bio-Rad, Hercules, CA).  
2.3.17 Micelle Exonuclease/Endonuclease Degradation via Gel Electrophoresis 
Three different micelle formulations were investigated for degradation after exposure to 
DNase I and exonuclease III (Thermo Fisher Scientific, Rockford, IL): FKN-S2-T10 
micelles, PEGylated FKN-S2-T10 micelles, and PEGylated control micelles. All micelles 
contained 20 mol% HEX-labeled ssDNA-amphiphiles and were prepared at 250 µM in 
water. Micelles were mixed into four separate conditions to test for nuclease degradation 
by using 2.5 µL of micelles and 47.5 µL of solution, for 50 µL total mixture: 0-5 U/mL in 
1X reaction buffer provided by the kit for DNase I, as well as 0-5 U/mL in 1X reaction 
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buffer provided by the kit for exonuclease III. Micelle solutions were incubated at 37 °C 
for 24 h, run on 2% agarose gels at 120V for 40 min, and imaged using a ChemiDoc MP 
Imaging System (Bio-Rad, Hercules, CA).  
2.3.18 Copper Chelation Assay 
64Cu is a popular isotope due to its 12.7 h half-life, allowing PET scans for up to 48 h after 
injection.125 To verify that copper would bind to DOTA-labeled FKN-S2-T10-amphiphiles 
a copper chelation assay was designed. Copper (Cu2+) standard solutions ranging between 
0 and 40 µM were created by mixing a 100 µM CuCl2 stock solution with water, and then 
diluted by a factor of two using 100 mM sodium acetate, buffered to pH 6 with acetic acid, 
thus creating solutions ranging between 0 and 20 µM Cu2+ in 150 µL of total solution. 
Additional samples of 10 µM Cu2+ were created via the same method to be mixed with 
ssDNA micelles containing 5 mol% DOTA-labeled FKN-S2-T10-amphiphiles, 47.5 mol% 
PEGylated FKN-S2-T10-amphiphiles, and 47.5% FKN-S2-T10-amphiphiles. Samples with 
DOTA:Cu2+ ratios varying between 1 and 10 were created by mixing 15 µL of 100 µM 
CuCl2 solution, 500 µM DOTA-labeled micelles in water (1.5 µL for equimolar through 
15 µL for 10X excess), 15 µL of 10X PBS, and diluted to 150 µL total volume with water. 
All solutions were lightly vortexed and incubated at 37 °C for 1 h. To precipitate the ssDNA 
and leave only the free, unchelated Cu2+ in solution, 1 mL of 2.5% (w/v) LiClO4 in acetone 
was added to all solutions, vortexed, and incubated at -20 °C for 15 min. The solutions 
were centrifuged for 15 min at 16,100g and the supernatant was collected and dried 
completely overnight in a heated vacuum. Dried samples were rehydrated with 100 µL 
water and incubated with a Copper Assay Kit according to the manufacturer’s instructions. 
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The absorbance of each sample was measured at 359 nm to determine the amount of free 
Cu2+ in solution. Linear regression was performed on triplicate measurements of the 
standard solutions. The results of this regression were used to determine the concentration 
of unchelated Cu2+ left in the DOTA-labeled ssDNA samples (n = 3).  
2.3.19 Micro-positron Emission Tomography (µPET)/Computerized Tomography(CT) 
Imaging of Animal Model 
MCA-38.FKN cells were suspended in 1X PBS at 106 cells/mL. 100 µL of the cell 
suspension was injected into subcutaneous space of the shoulder of Jackson J:Nu female 
homozygous mice (Jackson Labs, Bar Harbor, ME). Tumors were allowed to grow to 
approximately 1 mL in volume before mice were injected with 64Cu-DOTA-labeled 
micelles. Micelle samples with FKN-S2-T10 aptamer-amphiphiles or control-amphiphiles 
containing 5 mol% DOTA-labeled ssDNA-amphiphiles, 47.5 mol% PEGylated ssDNA-
amphiphiles, and 47.5% ssDNA-amphiphiles at 250 µM were diluted to 150 µM in 2X 
PBS. The 64Cu (Department of Medical Physics, University of Wisconsin, Madison) was 
diluted to 2 µCi/µL in 100 mM sodium acetate in water at pH=6, mixed with the micelle 
solution (1:1 v/v) and incubated at 37 °C for 1 h to give a final ssDNA-amphiphile 
concentration of 75 µM in 1X PBS and 1 µCi/µL of 64Cu.  
Mice were placed under a heat lamp prior to injections to dilate the veins in their tails. The 
tails were wiped with ethanol swabs to clean them prior to injection and 200 µL of the 
64Cu-labeled micelle solution was injected into the lateral tail veins of the mice. The final 
solution to be injected contained approximately 0.8 pmol 64Cu and 1.5 nmol of DOTA, 
approximately 1,850X molar excess of DOTA to 64Cu. The radioactivity and time of 
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measurement of each individual syringe was measured immediately before and after tail 
vein injections. 15 min prior to each imaging time point (1, 3, 24 h after injection), mice 
were anesthetized using 3% isofluorane in oxygen at 0.8 L/min flow. µPET and CT scans 
were taken on a Siemens Inveon µPET/CT scanner (Center for Magnetic Resonance 
Research, University of Minnesota). After the 1 h and 3 h imaging time points, mice were 
placed under a heat lamp until they regained consciousness. After the 24 h time point, mice 
were euthanized for ex vivo organ radioactivity measurements. 
All animal work in this chapter was approved by the IACUC at the University of Minnesota 
– Twin Cities. 
2.3.20 In Vivo Biodistribution Analysis 
Manual segmentation of CT scans to identify the location of each organ is cumbersome 
and prone to bias, so Digimouse,126 a reference dataset, was used. Digimouse provides a 
CT scan of a mouse, together with an image where each pixel is assigned a label 
corresponding to the organ at that location, also known as atlas. Images of two to four mice 
were acquired simultaneously, so the first step was to separate the CT and µPET images 
into two to four images of each individual mouse. This was done using a custom interactive 
tool written for MevisLab (http://www.mevislab.de). Care was taken to maintain the 
coordinate system and the calibrated radiological values contained in the original DICOM 
files.  
The workflow of the µPET/CT image analysis is illustrated in Figure S12. To avoid 
artifacts in calculating the transformation, the tumor area was excluded from the 
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estimation. The tumor was segmented using ITK-SNAP, a free open-source software to 
perform semi-automatic segmentation using adaptive contours. First, an upper and lower 
threshold were used to separate the tumor tissue from the surrounding material and 
determine the direction and speed of the adaptive contour in the next step; then, the union 
of a few spherical ROIs were used to initialize the contour; finally, the contour went 
through several steps of evolution to adapt itself to the shape of the tumor.  
To find the transformation from the CT image of the Digimouse to the CT image from the 
scanned mouse, a three-step registration workflow was performed: rigid-body, affine and 
elastic transformation model based on B-Splines. Elastix, a free open-source software was 
used for elastic registration. The tumor segmentation was used as an exclusion region 
during the estimation of the transformation. The resulting transformation was then applied 
to the atlas from Digimouse using a nearest-neighbor approximation, and the transformed 
atlas was combined with the segmentation of the tumor by assigning a new, unassigned 
label to every pixel in the tumor. The resulting atlas was in the coordinate system and 
spacing of the CT image, so the following step was to transform the atlas into the coordinate 
system and spacing of the µPET image using the “applyTransform” command from the 
ANTs toolbox (http://stnava.github.io/ANTs/), with the atlas as input, specifying no 
transformation and indicating the µPET image as reference. The µPET image radiation was 
quantified for each region in the resulting atlas. R in RStudio was finally used to extract 
the measurements of interest and export the data into an Excel table.  
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Radiation values tabulated from this analysis were decay-adjusted to allow comparisons at 
different time points. The total injected dose was calculated by measuring the time-
normalized radiation in the syringe prior to injection and subtracting the time-normalized 
radiation in each syringe after injection as well as the time-normalized radiation in each 
mouse’s tail after 24 h as measured from the ex vivo analysis. The tail value was subtracted 
due to the possibility of missing the vein during injection thus, limiting the amount of 64Cu 
delivered to the whole body. The volume of each organ was converted to mass based on 
literature values for organ densities.127, 128 The radiation values for each organ were 
adjusted for the decay of 64Cu (12.7 h half-life). Data were plotted as percent injected dose 
per gram of tissue (%ID/gr) and student’s t-test statistical analysis was used to evaluate 
statistical significance.  
2.3.21 Ex Vivo Biodistribution Analysis 
After the in vivo µPET/CT data were collected at the 24 h time point, mice were euthanized 
to collect organs for ex vivo measurements. Organs were excised and weighed to determine 
the mass. The radioactivity of each organ (kcpm) was recorded using a scintillator and 
converted to µCi using a calibration curve. The radiation values for each organ were 
adjusted for the decay of 64Cu. The total injected dose was calculated as discussed above. 
Data were plotted as %ID/gr and compared with student’s t-test statistical analysis.  
2.3.22 Confocal Microscopy of Tumors 
Mice were given subcutaneous MCA-38.FKN tumors using the same procedure as for the 
µPET/CT imaging. 200 µL of micelles with FKN-S2-T10 aptamer-amphiphiles or control-
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amphiphiles consisting of 20 mol% FAM-labeled ssDNA-amphiphiles, 40 mol% 
PEGylated ssDNA-amphiphiles, and 40 mol% ssDNA-amphiphiles at 75 µM in 1X PBS 
were injected into the lateral tail vein of mice. After 24 h mice were euthanized, tumors 
excised and frozen in isopentane cooled by dry ice. Unstained frozen sections were cut (5 
µm) and air dried overnight. The following day the slides were put into a tap water rinse 
for 5 min to hydrate and then moved to TBST buffer. Endogenous peroxidase activity was 
quenched by slide immersion in 3% hydrogen peroxide solution for 10 min followed by 
TBST rinse.  A serum-free blocking solution, Rodent Block M (Biocare Medical, Concord, 
CA), was placed on sections for 1 h.  Blocking solution was removed and slides were 
incubated in Wheat Germ Agglutinin AlexaFluor594 Conjugate (Thermo Fisher Scientific, 
Rockford, IL) used at a 1:200 dilution overnight at 4 °C. The next morning the slides were 
put into a TBST rinse followed by a 5 min incubation in 12.3 μg/mL Hoescht 33342 
(Thermo Fisher Scientific, Rockford, IL). The slides were rinsed twice with TBST, 5 min 
each then into distilled water and cover slipped using VectaSheild anti-fading mounting 
media (Vector Laboratories, Burliggame, CA). Slides were kept frozen until imaging on 
an Olympus FluoView FV1000 BX2 Upright Confocal Microscope (University Imaging 
Centers, University of Minnesota).  
2.4 Results 
2.4.1 Synthesis and Characterization of Micelles 
Synthesis steps for all ssDNA-amphiphiles are shown in Figure 2.1.  Successful synthesis 
was verified using LC-MS (Table 2.1) as well as 1H NMR (Figure 2.2, 2.3), showing the 
expected products from each reaction. Figure 2.4A shows the chemical structures of the 
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different ssDNA-amphiphiles used in this study. In order to investigate the effect of 
PEGylation on the targeting capability of the aptamer-amphiphiles, micelles were created 
with 0, 45 and 90 mol% PEGylated FKN-S2-T10 aptamer-amphiphiles (Figure 2.4B shows 
a cartoon of a PEGylated ssDNA micelle). 
 
Figure 2.1 Synthesis schemes of ssDNA-amphiphiles (A) with or without fluorophores, (B) with PEG5000, 
(C) with DOTA. The insets show the structures of the different probes attached to the 5’ end of the ssDNA. 
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Table 2.1. Expected and measured masses of ssDNA-amphiphiles as determined by LC-MS. 
Amphiphiles Expected mass (M-H) Observed mass (M-H) 
FKN-S2-T10 16,615.7 16,614.9 
HEX-FKN-S2-T10 17,359.4 17,359.2 
Cy5-FKN-S2-T10 17,147.9 17,147.4 
DOTA-FKN-S2-T10 17,693.6 17,693.0 
Control 16,076.0 16,076.0 
DOTA-Control 17,066.6 17,066.2 
 
 
Figure 2.2. 1H NMR of FKN-S2-T10 aptamer-amphiphile and PEG5000-FKN-S2-T10 aptamer-amphiphile in 
98% H2O / 2% D2O verifying PEGylation of the ssDNA-amphiphile. 
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Figure 2.3. 1H NMR of FKN-S2-T10 aptamer-amphiphile and DOTA-FKN-S2-T10 aptamer-amphiphile in 
98% H2O / 2% DMSO-d6 verifying DOTA conjugation. 
 
Figure 2.4. (A) Chemical structures of different ssDNA-amphiphiles used to create micelles. (B) Schematic 
representation of a PEGylated ssDNA micelle, where the ssDNAs are shown in blue (not showing any 
secondary structure), the hydrophobic tails in gray, PEG in green, and labels in red. Not drawn to scale. (C) 
Cryo-TEM of FKN-S2-T10 micelles with 45 mol% PEGylated FKN-S2-T10 aptamer-amphiphiles. 
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Zeta potential and sizes of different micelles are reported in Table 2.2. There was no 
statistically significant difference between groups with different concentrations of 
PEG5000, demonstrating no change in size or charge upon addition of PEG. Cryo-TEM 
showed that all amphiphiles formed 12x10 nm weakly ellipsoidal micelles (a cryo-TEM 
for the 45 mol% PEGylated FKN-S2-T10 micelles is shown in Figure 2.4C). DLS gave an 
average diameter of 18, 22 and 22 nm for the 0, 45 and 90 mol% PEGylated FKN-S2-T10 
micelles respectively.  
Table 2.2. Size and zeta potential of micelles with varying degrees of PEGylation. Data are presented as the 
mean ± SE.  Student’s t-test analysis showed that there was no statistically significant difference between 
groups with different concentrations of PEG5000. 
 
Micelles 
Major x minor axis             
from cryo-TEM                   
(nm) 
Hydrodynamic 
diameter from 
DLS (nm) 
Zeta 
potential 
(mV) 
0 mol% PEG5000-FKN-S2-T10 12.5 ± 0.3 x 10.3 ± 0.3 18.4 ± 2.3 -18 ± 2 
45 mol% PEG5000-FKN-S2-T10 12.3 ± 0.5 x 10.3 ± 0.3 22.1 ± 0.9 -17 ± 3 
90 mol% PEG5000-FKN-S2-T10 12.0 ± 0.3 x 9.6 ± 0.3 21.7 ± 1.1 -15 ± 3 
45 mol% PEG5000-Control 11.9 ± 0.3 x 8.6 ± 0.2 17.2 ± 1.8 -17 ± 4 
 
The free FKN-S2 aptamer formed a G-quadruplex and stem-loop secondary structure in 
PBS (Figure 2.5).121 When conjugated to a T10 spacer-dialkyl tail, such as the one used in 
this study, the FKN-S2-T10-amphiphiles self-assembled into micelles with a critical micelle 
concentration of around 50 nM, forming intermolecular G-quadruplexes within the 
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micelle.121 CD was performed for the 0, 45 and 90 mol% PEGylated micelles and it was 
shown that all micelles showed a positive peak at 265-266 nm and a negative peak at 241-
242 nm, characteristic of parallel G-quadruplex (Figure 2.6). However, the addition of 
PEG5000 to the 90 mol% PEGylated micelles did cause a change in the intensity of the 
peaks, suggesting that the G-quadruplex may have been destabilized to a certain extent.  
 
Figure 2.5. Cartoon of the secondary structure of the FKN-S2 aptamer. 
 
Figure 2.6. CD spectra of 5 µM FKN-S2-T10 aptamer-amphiphiles with different amounts of PEG5000 in 1X 
PBS. All micelles showed a positive peak at 265-266 nm and a negative peak at 241-242 nm characteristic 
of parallel G-quadruplex. 
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2.4.2 In Vitro Delivery of Micelles 
Fractalkine expression was verified via flow cytometry for MCA-38.FKN cells and BJ 
fibroblasts (Figure 2.7A, 2.7B). Binding and internalization of FKN-S2-T10 micelles, and 
the effect of PEG5000 addition to cell association were first evaluated in vitro via flow 
cytometry. Fluorescence was normalized to the average surface area of each cell type to 
account for the substantial difference in cell size. Results in Figure 2.8 showed that 
MCA.38-FKN cells had a much higher associated fluorescence per area than BJ fibroblasts 
for each micelle mixture. Additionally, the non-PEGylated micelles had the highest 
fluorescence per area when delivered to MCA-38.FKN cells, while there was no statistical 
difference between the 45 and 90 mol% PEGylated micelles. There was also no statistically 
significant difference between the cell association of the three micelle formulations when 
delivered to BJ fibroblasts. Even though the addition of PEG5000 inhibited binding and 
internalization of FKN-S2-T10 micelles to the MCA-38.FKN cells to some extent, 
PEGylated micelles were used for further studies, as PEG has been shown to improve 
serum stability, blood circulation and immunogenic response of nanoparticles, resulting in 
higher tumor accumulation.129, 130 Throughout the remaining experiments, all micelles 
(referred to as PEGylated micelles) were formulated with the smallest percentage of probe-
labeled amphiphiles that would provide a satisfactory signal-to-noise ratio. The remaining 
percentage of amphiphiles was split evenly between PEGylated and non-PEGylated 
amphiphiles. Table 1 shows all micelle compositions for each experiment performed in this 
study. 
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Figure 2.7. Fractalkine expression on (A) MCA-38.FKN cells, (B) BJ fibroblast cells, and (C) HCoEpiC. 
 
Figure 2.8. Binding and internalization of FKN-S2-T10 micelles with different amounts of PEG5000 by MCA-
38.FKN and BJ fibroblasts after 24 h at 37 °C. Fluorescence was normalized to cell area. Data are presented 
as mean±SE (n=3). A two-way ANOVA with Tukey’s HSD post-hoc analysis indicated that all pairs showed 
significant statistical difference (p<0.05) with the exception of the ones with † (p>0.05). 
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The presence of free aptamer decreased binding of PEGylated FKN-S2-T10 micelles to 
MCA-38.FKN cells by 50%, showing effective blocking (Figure 2.9). Confocal 
microscopy was performed on MCA-38.FKN and BJ fibroblasts incubated with PEGylated 
FKN-S2-T10 micelles to determine the extent of binding and internalization for each cell 
type. The MCA-38.FKN cells (Figure 2.10A) showed high amounts of micelle 
internalization, while the BJ fibroblasts (Figure 2.10B) showed mainly surface binding 
with minimal micelle internalization. In the MCA-38.FKN cells the micelles were present 
in both the cytosol and acidic organelles, but were mainly distinct from the early 
endosomes (Figure 2.11).  
 
Figure 2.9. Blocking of FKN-S2-T10 micelles in the presence of free FKN-S2-T10 aptamer. The micelles were 
composed of 20 mol% HEX-labeled FKN-S2-T10 aptamer-amphiphiles, 40 mol% PEGylated FKN-S2-T10 
aptamer-amphiphiles and 40 mol% FKN-S2-T10 aptamer-amphiphiles. MCA-38.FKN cells were blocked 
with free FKN-S2-T10 aptamer for 1 h at 4 °C, followed by incubation with the micelles for an additional 1 h 
at 4 °C. 
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Figure 2.10. Confocal microscopy of PEGylated FKN-S2-T10 micelles incubated for 24 h at 37 °C with (A) 
MCA-38.FKN cells, or (B) BJ fibroblasts. Micelles are shown in green, nuclei in gray and cell membranes 
in red. 
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Figure 2.11. (A) Intracellular distribution of PEGylated FKN-S2-T10 micelles in MCA-38.FKN cells. (B) 
Zoom in of the square area shown in A. Micelles are shown in red, early endosomes in blue, acidic organelles 
in green and nuclei in gray. 
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Cell binding and internalization of PEGylated FKN-S2-T10 micelles by HCoEpiC that did 
not express fractalkine (Figure 2.7C) was also examined. HCoEpiC showed minimal cell 
association via flow cytometry compared to MCA-38.FKN cells (Figure 2.12A), and 
minimal surface binding with no internalization via confocal microscopy (Figure 2.12B). 
 
Figure 2.12. (A) Binding and internalization of PEGylated FKN-S2-T10 micelles by HCoEpiC after 24 h at 
37 °C. Data are presented as mean±SE (n=3). Student’s t-test analysis was used to determine significance, * 
p<0.001. (B) Confocal microscopy of PEGylated FKN-S2-T10 micelles incubated for 24 h at 37 °C with 
HCoEpiC. Micelles are shown in green, nuclei in gray and cell membranes in red. 
2.4.3 Micelle Stability to Serum and Nucleases 
The stability to serum and nucleases was investigated for the PEGylated FKN-S2-T10 and 
PEGylated control micelles that were used for the in vivo studies. Non-PEGylated FKN-
S2-T10 micelles were also used as a control to test the effect of PEG5000. All micelles 
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contained HEX-labeled ssDNA-amphiphiles that gave rise to the micelle signal in the gels. 
The micelles were exposed to 1X PBS, 10% FBS in water to mimic in vitro conditions, 
and 90% FBS in water to mimic in vivo conditions, for 24 h at 37 °C (Figure 2.13). Controls 
without micelles were also included to capture the autofluorescence of serum proteins. 
Upon exposure to 10% and 90% FBS the micelle band decreased and shifted upwards, even 
in the presence of PEG, and the band associated with serum proteins became stronger, for 
all micelles. Comparison between the PEGylated FKN-S2-T10 micelles and PEGylated 
control micelles showed that the micelle band was stronger, and the serum band was 
weaker for the PEGylated control micelles in the presence of 90% FBS. The stability of 
micelles to DNase I (Figure 2.14) and exonuclease III (Figure 2.15) at 0-5 U/mL for 24 h 
at 37 °C was also examined, and all micelles were stable at all concentrations for both 
nucleases.  
 
Figure 2.13. Gel analysis of ssDNA micelles incubated at 37 °C for 24 h in 1X PBS, 10% (v/v) FBS in water 
to mimic in vitro conditions, and 90% (v/v) FBS in water to mimic in vivo conditions. Controls without 
micelles were also included to capture the autofluorescence of serum proteins. All formulations had 20 mol% 
HEX-labeled ssDNA-amphiphiles that gave rise to the micelle signal. 
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Figure 2.14. Gel analysis of ssDNA micelles incubated with 0-5 U/mL DNase I at 37 °C for 24 h. All 
formulations had 20 mol% HEX-labeled ssDNA-amphiphiles that gave rise to the micelle signal. 
 
Figure 2.15. Gel analysis of ssDNA micelles incubated with 0-5 U/mL exonuclease III at 37 °C for 24 h. All 
formulations had 20 mol% HEX-labeled ssDNA-amphiphiles that gave rise to the micelle signal. 
54 
 
2.4.4 Biodistribution and Tumor Internalization of Micelles in an Animal Model 
The biodistribution of PEGylated FKN-S2-T10 micelles and PEGylated control micelles 
was determined in vivo using µPET/CT. DOTA-labeled ssDNA-amphiphiles was used to 
chelate 64Cu. DOTA labeling has been shown to have a minor effect on the size and surface 
charge of nanoparticles.131, 132 DOTA-labeled amphiphiles were present in approximately 
1,850X molar excess of 64Cu in order to chelate all added 64Cu. This was demonstrated by 
showing that copper was chelated by DOTA-labeled ssDNA micelles when DOTA was 
present at 5X-10X molar excess (Figure 2.16).   
 
Figure 2.16. Concentration of unchelated Cu2+ remaining in solution after treatment with DOTA-labeled 
ssDNA micelles (present at 1X, 5X, and 10X molar excess of Cu2+), as determined by the calibration curve. 
The micelles were composed of 5 mol% DOTA-labeled FKN-S2-T10-amphiphiles, 47.5 mol% PEGylated 
FKN-S2-T10-amphiphiles, and 47.5% FKN-S2-T10-amphiphiles. Data are presented as mean ± SE (n=3). For 
the in vivo studies, 64Cu-labeled micelle solutions contained approximately 1,850X molar excess of DOTA 
to 64Cu. 
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Representative µPET/CT three-dimensional volume renderings of mice at 1, 3 and 24 h are 
shown in Figure 2.17A (not adjusted for 64Cu decay), while the in vivo biodistribution of 
the PEGylated FKN-S2-T10 and control micelles from the µPET images is plotted for each 
organ in Figure 2.17B. As shown in Figure 2.17B there was no statistically significant 
difference between the PEGylated FKN-S2-T10 and PEGylated control micelles for most 
organs within a given time point. The biodistribution of the PEGylated FKN-S2-T10 
micelles over time showed no statistical difference between 1 and 3 h, with the exception 
of pancreas, or between 1 and 24 h, with the exception of liver. However, for many organs 
the 3 h time point was statistically higher than 24 h, thus showing a point of high 
accumulation between 1 and 3h and a decline after that. Similarly, the biodistribution of 
the PEGylated control micelles over time showed no statistical difference between 1 and 3 
h, or 1 and 24 h for most organs. The PEGylated control micelles showed higher 
accumulation at 3 h compared to 24 h only for some organs (skin, liver, lungs and bladder) 
though. There was no statistically significant difference in the accumulation of the 
PEGylated FKN-S2-T10 or control micelles in the tumor over time.  
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Figure 2.17. (A) Representative mice with subcutaneous MCA-38.FKN tumors shown as three-dimensional 
volume renderings of coronal µPET (orange) overlaid on CT images (gray) at 1, 3 and 24 h after intravenous 
tail injection of 64Cu-DOTA-labeled PEGylated FKN-S2-T10 micelles (top), or 64Cu-DOTA-labeled 
PEGylated control micelles (bottom). (B) Biodistribution of micelles at 1, 3 and 24 h post injection from 
µPET images. Data were adjusted for 64Cu decay and plotted as mean±SE (n=3-6). P-values from student’s 
t-test analysis can be found in Table 2.3. 
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Table 2.3 P-values from the student’s t-test analysis of in vivo biodistribution data for 64Cu-DOTA-labeled 
PEGylated FKN-S2-T10 or control micelles at 1, 3, and 24 h post intravenous tail injection, shown in Figure 
2.17B. 
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The ex vivo biodistribution data at 24 h in Figure 2.18 showed no statistically significant 
difference between the PEGylated FKN-S2-T10 and PEGylated control micelles for any 
organ measured, with the exception of blood where control micelles were present more 
than the FKN-S2-T10 micelles. Tumor delivery was approximately 4% ID/gr for both 
micelles, and the organs with the highest delivery at 24 h were the liver and kidneys for 
both nanoparticles. In contrast, the in vivo biodistribution (Figure 2.17B) showed the liver 
as the only organ with high accumulation at 24 h.  
 
Figure 2.18. Ex vivo biodistribution of 64Cu-DOTA-labeled PEGylated FKN-S2-T10 micelles or 64Cu-DOTA-
labeled PEGylated control micelles, in MCA-38.FKN tumor-bearing mice, 24 h post intravenous tail 
injection. Data were adjusted for 64Cu decay and plotted as mean±SE (n=4-5). Student’s t-test analysis was 
used to determine significance, * p<0.05. There was no significant statistical difference for pairs without 
brackets. 
We hypothesized that although tumor uptake was similar between the PEGylated FKN-S2-
T10 and control micelles, only the FKN-S2-T10 micelles internalized into the tumor cells. 
Figure 2.19 shows confocal microscopy images of MCA-38.FKN tumor sections 24 h post 
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intravenous tail injection of FAM-labeled PEGylated FKN-S2-T10 and PEGylated control 
micelles. The PEGylated FKN-S2-T10 micelles showed significant internalization by the 
tumor cells and colocalization with the nuclei, while the PEGylated control micelles were 
mainly located on the extracellular space or associated with the cell membrane.  
 
Figure 2.19. Confocal microscopy of tumor sections 24 h post intravenous tail injection of (A) FAM-labeled 
PEGylated FKN-S2-T10 micelles, or (B) FAM-labeled PEGylated control micelles. Membranes are shown in 
red, nuclei in gray and micelles in green. 
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2.5 Discussion 
In this report, we used FKN-S2-T10 aptamer-amphiphiles to create micelles that could 
target fractalkine-expressing cancer cells. The micelles were decorated with PEG5000, as 
PEG has been shown to decrease nanoparticle immunogenicity and increase blood 
circulation time, which improves tumor accumulation.133, 134 Cryo-TEM revealed that the 
FKN-S2-T10 aptamer-amphiphiles self-assembled in weakly ellipsoidal micelles, as has 
been observed before for ssDNA-amphiphiles that form G-quadruplexes.135 The difference 
in micelle diameters between cryo-TEM and DLS is attributed to the fact that electron 
contrast in TEM derives mostly from the core,136, 137 while DLS reports the hydrodynamic 
diameter of the spheres that is larger than their true diameter. Therefore, it is likely that the 
actual diameter of the micelles falls between 12 and 22 nm. 
MCA-38.FKN cells and BJ fibroblasts were used initially to determine the effect of 
PEGylation on the binding and internalization ability of the micelles. FKN-S2-T10 micelles 
(PEGylated or not) associated at higher numbers with fractalkine-expressing MCA-
38.FKN cells compared to BJ fibroblasts that did not express fractalkine. PEGylation 
decreased binding of the FKN-S2-T10 micelles to MCA-38.FKN cells, but the amount of 
PEGylation (45 or 90 mol%) did not make a difference. In contrast, the non-specific 
binding of FKN-S2-T10 micelles to BJ fibroblasts was unaffected by PEG. Although the 
non-PEGylated micelles showed the highest binding and internalization when delivered to 
the MCA-38.FKN cells, micelles with partial PEGylation were selected for further 
experiments to take advantage of the advantages PEG confers to nanoparticles.  PEGylated 
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FKN-S2-T10 micelles were also evaluated with HCoEpiC and showed minimal cell 
association compared to MCA-38.FKN cells. 
Confocal imaging was performed to determine the extent of internalization versus non-
specific membrane association for the healthy and tumor cells. After 24 h, membrane-
associated cell binding was mainly observed for the BJ fibroblasts and HCoEpiC, while 
the MCA-38.FKN cells internalized the micelles to a much greater extent. The micelles 
were mainly found free in the cytosol of MCA-38.FKN cells, with some colocalization 
with acidic organelles. The results of confocal microscopy and blocking experiment 
performed in the presence of free aptamer, suggested that the PEGylated FKN-S2-T10 
micelles bound and internalized to fractalkine-expressing cells in a specific manner, in 
agreement with previous work showing that the FKN-S2 aptamer bound to fractalkine with 
high affinity and specificity.103  
The stability of the PEGylated FKN-S2-T10 and control micelles was evaluated in the 
presence of serum and nucleases after 24 h. Gel experiments suggested that serum proteins 
adsorbed onto the micelles, even in the presence of partial PEGylation, desorbing 
amphiphiles from the micelles. These results were in agreement with findings from the 
literature, where it was shown that the main mechanism of serum degradation for 
PEGylated ssDNA-gold nanoparticles was protein-mediated strand desorption and 3’-
exonucleases.123 It was also shown that 5’-exonucleases did not play a significant role in 
ssDNA breakdown, and PEG5000 protected the nanoparticles from aggregation mediated by 
serum proteins.123 Protein adsorption and amphiphile desorption from the micelles 
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appeared weaker in the case of PEGylated control micelles, in agreement with previous 
work showing that poly-T ssDNA sequences bound less serum proteins than G-rich 
ssDNA.138 The stability of micelles to endonuclease DNase I and exonuclease III was also 
evaluated. Exonuclease III was used as, in addition to the 3’-hydroxyl termini of double-
stranded DNA, it was shown to be active towards the 3’-end of ssDNA,139 and we wanted 
to examine if 3’-end conjugation of the ssDNA to the tail provided protection from 3’-
exonucleases. Results showed that all micelles were stable to both nucleases for all 
concentrations tested (0-5 U/mL). In fact, it was demonstrated in the literature that 50 
U/mL of DNase I was needed for degradation of ssDNA on gold nanoparticles protected 
by PEGylation, which was 500 times higher than the physiological mouse serum 
concentration of DNase I (0.1 U/mL).123 It should be noted that the average DNase I 
concentration in the blood plasma of healthy humans was 0.356±0.410 U/mL, while a 
decrease in DNase I activity below detection level was reported for colon cancer 
patients.140 Our results also demonstrated that both PEGylated and non-PEGylated FKN-
S2-T10 micelles were stable to both nucleases, as it was shown in the literature that steric 
hindrance through dense ssDNA packing in a micelle corona limits accessibility of 
nucleases.139 
The biodistribution of PEGylated FKN-S2-T10 and control micelles was investigated and 
results showed that absolute values between in vivo and ex vivo biodistribution data were 
different reflecting the different approaches of these two methods.141 For example, small 
differences in the perceived border of an organ in CT could result in large differences in 
radioactivity, while differences in blood flow before and after euthanasia can lead to 
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differences in measured radiation. From the time points examined through µPET images, 
there seemed to be a peak retention time between 1 and 3 h and a decline after that for most 
organs for the aptamer micelles. Similar to most intravenously injected nanoparticles, a 
prominent liver uptake of both micelles was detected at all times examined though µPET, 
which declined over time. The PEGylated control micelles though were present at higher 
amounts in heart, which is a highly perfused organ, at 1 and 3 h compared to PEGylated 
FKN-S2-T10 micelles. This result, along with the presence of more control micelles in the 
blood at 24 h in the ex vivo biodistribution data, suggested that the control micelles 
remained in blood circulation more than the aptamer micelles. Even though both micelles 
had the same PEGylation, the difference may lie in the actual ssDNA sequence of the 
micelles. Our serum stability results suggested that serum proteins adsorbed less on the 
PEGylated control micelles that lacked guanines, in agreement with previous findings in 
the literature.138 Thus, binding of a higher amount of opsonins on the surface of PEGylated 
FKN-S2-T10 micelles compared to the control micelles was possible, which could be 
followed by phagocytosis and rapid clearance from the blood stream.142  
The ex vivo biodistribution results at 24 h showed no statistically significant difference 
between the micelles for any organ measured, with the exception of blood for the control 
micelles. The lack of statistical differences between the two groups is not surprising, as 
biodistribution depends on the size, charge and shape of the nanoparticle.94, 98 The excised 
organs with the highest delivery were the liver and kidneys for both nanoparticles. The 
nature of the kidney accumulation was not clear, as nanoparticles smaller than our micelles 
(<10 nm in diameter) experience renal clearance.143 Kidney radioactivity is unlikely to be 
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due to the presence of free copper, either from unchelated copper or copper released in vivo 
due to kinetic instability of 64Cu-DOTA complexes, as copper accumulates mainly in the 
liver.125, 144 However, 64Cu-DOTA complexes accumulate in the kidneys,131 and therefore 
the presence of desorbed radiolabeled amphiphiles may be a possible explanation for the 
kidney accumulation for both micelles.  
Tumor delivery at 24 h post injection was approximately 4% ID/gr for both the aptamer 
and control micelles, similar to tumor accumulation observed by other micelles.125, 145 
There was no statistically significant difference in the accumulation of PEGylated FKN-
S2-T10 or control micelles in the tumor over time from the µPET images, or at 24 h based 
on values of excised tumors. However, confocal imaging of tumors demonstrated that 
PEGylated FKN-S2-T10 micelles internalized into the MCA-38.FKN cells while 
PEGylated control micelles did not. In particular, there was significant colocalization of 
the targeted micelles with the nuclei. In contrast, the control micelles were mainly located 
on the extracellular space or associated with the cell membrane. This showed that both 
micelles were able to extravasate and enter the tumor independent of the ssDNA sequence 
used, but were only able to internalize into the fractalkine-expressing tumor cells when 
they were composed of the FKN-S2-T10 aptamer-amphiphile. Our results were consistent 
with literature reports showing that targeting did not help in tumor accumulation or 
retention over time, as both targeted and non-targeted PEGylated nanoparticles 
demonstrated nearly identical tumor localization kinetics and accumulation after 24 h.131, 
146 Instead, it was shown that targeting contributed to enhanced internalization by the tumor 
cells.147 
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In conclusion, we have shown for the first time the development, characterization and 
targeting efficacy of PEGylated FKN-S2-T10 micelles for human fractalkine in vitro and in 
vivo. Partial PEGylation minimized non-specific interactions with healthy cells without 
compromising the secondary structure of the aptamer, or binding and internalization into 
fractalkine-expressing colon cancer cells. Serum adsorption was observed that may have 
contributed to amphiphile desorption from the micelles, but both aptamer and control 
micelles were highly resistant to nucleases. In vivo biodistribution of PEGylated FKN-S2-
T10 and control micelles showed that tumor uptake was independent of the ssDNA 
sequence, but the aptamer was required for binding and internalization into the fractalkine-
expressing tumor cells in vivo.  
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3 Delivery of ssDNA-Amphiphile Nanotubes to 
Glioblastoma Multiforme 
3.1 Summary 
In this work, we evaluated the ability of nanotubes made out of guanine-rich self-assembled 
ssDNA-amphiphiles to bind and internalize to GL261 mouse glioblastoma cells. Stability 
tests showed that the nanotubes did not degrade when exposed to 10% or 85% serum, or 
nucleases for 24 h. Confocal microscopy images showed that after 24 h, the nanotubes 
internalized by GL261 cells but not by C8-D1A healthy mouse astrocytes. For comparison, 
spherical micelles made out of the same ssDNA-amphiphiles did not internalize to either 
GL261 or C8-D1A cells. Intracellular trafficking analysis showed that the nanotubes 
internalized to GL261 by endocytosis, and after 24 h they were found in endosomes, 
lysosomes and free in the cytosol.  Delivery of the nanotubes was also investigated in vivo 
in an orthotopic GL261-bearing mouse model. Direct brain injections of the nanotubes 
showed only the side of the brain with the tumor retained the nanotubes, while the 
nanotubes were not visible in the healthy tissue. In vivo biodistribution of the nanotubes 
after their systemic delivery also showed high brain accumulation, thus demonstrating their 
promise as a drug delivery vehicle for glioblastoma. 
3.2 Introduction 
Targeted drug delivery vehicles have become a promising field for delivery of therapeutics 
to brain cancers. Tumor targeting in general is aided by the enhanced permeability and 
retention (EPR) effect,2 but targeting of the brain is made more difficult by the blood-brain-
barrier (BBB), which acts to limit the transport of large-molecule drugs to the brain.148 
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Glioblastoma multiforme (GBM) is the most malignant type of primary brain tumor. 
Despite treatment through neurosurgery, radiation, and chemotherapy, long-term survival 
remains low. GBM has been shown to increase the permeability of the BBB,149-151 which 
combined with the EPR effect can help in the development of new treatment options.  
The delivery of nanoparticles to the brain as carriers for therapeutics is promising. The 
field of polymeric and liposomal nanoparticles is well developed, and both types of 
nanoparticles have been used extensively as delivery vehicles to the brain.152, 153 However, 
typical accumulation of targeted liposomal or polymeric nanoparticles 24 h after systemic 
injection are often lower than 0.5 percent injected dose per gram of tissue (%ID/g).154, 155 
It is therefore important to improve the accumulation of the nanoparticle delivery vehicle 
in the brain tissue so that more therapeutic can reach the tumor.  
Several options exist for increasing the accumulation of nanoparticles to their intended 
location. Targeting through the attachment of small-molecule peptides,156-158 antibodies,111, 
159, 160 or aptamers161, 162 has been shown to improve the retention of nanoparticles when 
delivered to GBM. The addition of poly (ethylene glycol) to nanoparticles has been shown 
to improve delivery and accumulation by improving the blood circulation and 
immunogenic properties of the nanoparticles,130, 163 thereby allowing for better 
accumulation by increasing the time exposed to the intended target. The shape and aspect 
ratio of a nanoparticle can also influence its cell association. In low Reynolds number 
flows, such as the blood capillaries, elongated particles align with the fluid flow in a 
phenomenon known as shear alignment. In the presence of targeting antibodies, this leads 
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to better retention of nanorods compared to nanospheres in the brain endothelium, with the 
targeted nanorods showing more than seven times greater brain uptake than targeted 
nanospheres of the same volume.71 Even in the absence of targeting, the internalization of 
positively charged hydrogel rod-like high-aspect-ratio nanoparticles was much more rapid 
and efficient than the internalization of particles of equal volume with an aspect ratio of 
one, showing the effect of shape on cell internalization.164 
Off-targeting effects also need to be minimized when delivering toxic loads. Therefore, it 
is important for nanoparticles to have varied uptake between cell types to increase delivery 
to target cells while limiting off-targeting to healthy cells. It has been shown that for non-
targeted nanoparticles, larger-sized negatively charged hydrogel nanodiscs and nanorods 
lead to better cellular internalization than their smaller counterparts.72 It was also shown 
that cell lines have differential preferences for internalizing nanodiscs or nanorods by using 
different pathways.72 This suggests that it is possible to identify nanoparticles whose 
intrinsic shape and size may allow for preferential accumulation in cancerous cells as 
compared to healthy cells.  
Single-walled carbon nanotubes functionalized with targeting moieties, such as small 
peptides or monoclonal antibodies, have been utilized to selectively target glioblastoma 
cells.165, 166 When delivered systemically through the tail vein to subcutaneous human 
glioblastoma xenograft tumors, these nanotubes showed efficient uptake by the 
subcutaneous glioblastoma tumors, but low overall brain accumulation,165 while in vitro 
studies showed that selective targeting via antibody incorporation can lead to effective cell 
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death whereby the targeted nanotubes can be used to induce photothermolysis of the 
targeted cells.166 Multi-walled carbon nanotubes have also shown effective cell targeting 
when functionalized with a BBB-crossing peptide, leading to the efficient delivery of 
doxorubicin and prolonged survival rates of mice bearing orthotopic glioblastoma 
tumors.167  
DNA nanotechnology is a growing field that allows for the creation of custom-designed 
nanoparticles. DNA origami168 and DNA tile assembly169 are two methods that allow for 
the assembly of specific nanoparticle structures composed solely of DNA molecules. Both 
techniques have been utilized to create DNA nanotubes that can deliver to cells in vitro and 
in vivo.170-174 It was shown that nanotubes made from tile assembly are internalized by 
immune cells, human cervical cancer cells, and nasopharyngeal epidermal carcinoma cells 
when targeted with either CpG sequences or folic acid.170-172 These tile-assembled 
nanotubes are more resistant to degradation than free ssDNA or double-stranded DNA 
(dsDNA) plasmids when exposed to serum conditions that mimic the in vivo environment 
170, 171. These nanotubes can also be used to deliver therapeutic loads such as small 
interfering RNA (siRNA).171 Nanotubes assembled in a tile-like manner also showed 
increased resistance to degradation when incubated with serum compared to a short 
oligonucleotide dsDNA sequence.173 These tile-like nanotubes also showed higher cellular 
internalization than free dsDNA molecules when delivered to human cervical cancer 
cells.173 DNA origami nanotubes have also been used to deliver doxorubicin to human 
breast cancer cells, where the origami nanotubes with doxorubicin showed higher cell death 
than free doxorubicin delivered alone.174 A major limitation of both DNA origami and 
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DNA tile assembly is that they require precise solvent and thermal conditions to allow for 
DNA annealing and often require computer-aided design to develop the required DNA 
sequences needed to achieve certain structures. It was shown that the sodium concentration 
available in 1X PBS is not sufficient to stabilize tile-assembled DNA nanotubes and that 
more than 4 mM Mg2+ was necessary to stabilize the structures.171    
Taking inspiration from the lipid and peptide-amphiphile self-assembly literature, we have 
previously developed ssDNA-amphiphiles that are capable of self-assembling in aqueous 
solution into spherical micelles, nanotapes and nanotubes. These amphiphiles consist of 
three main sections, a ssDNA hydrophilic headgroup, a C16 dialkyl hydrophobic tail, and a 
spacer used to separate the two other sections. We have shown that in the presence of a 
hydrocarbon spacer, spherical micelles and nanotubes with varying lengths can form from 
ssDNA-amphiphiles in aqueous solution.23, 24 One amphiphile in particular was identified 
as forming short ssDNA nanotubes in large quantities. This amphiphile consists of a ten 
nucleotide (nt) ssDNA headgroup containing five consecutive guanine (G) repeats attached 
to a dialkyl tail using a C12 hydrocarbon spacer. The structures formed from this amphiphile 
will be referenced as nanotubes or micelles for the remainder of this work.  
In this work we investigate the uptake of ssDNA nanotubes by the model mouse 
glioblastoma GL261 cell line without the addition of a targeting moiety. Using size 
exclusion chromatography, we separated the self-assembled nanoparticles based on their 
size, creating samples containing only self-assembled nanotubes or micelles. The serum 
and nuclease stability of the nanotubes was investigated to show they are resistant to 
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degradation in different culture conditions. The nanotubes and micelles were delivered to 
GL261 cells and imaged with confocal microscopy to demonstrate the preferential uptake 
of the nanotubes to glioblastoma cells. Further internalization experiments were used to 
determine the internalization pathways utilized by the nanotubes during cellular uptake. In 
vivo experiments using an orthotopic GL261 tumor model investigated the retention of 
nanotubes after direct brain injections as well as the biodistribution over time after systemic 
tail-vein injections via micro positron emission tomography (µPET)/computerized 
tomography (CT) and ex vivo organ analysis. Here were report the uptake of ssDNA 
nanotubes by GL261 cells based on the size characteristics of the nanoparticles as well as 
high overall brain accumulation by the nanotubes using in vivo models.  
3.3 Materials and Methods 
3.3.1 Materials 
All materials were purchased from Sigma Aldrich and used without further purification or 
modification unless otherwise stated. Buffers include high performance liquid  
chromatography (HPLC) buffer A (100 mM hexafluoroisopropanol and 15 mM 
triethylamine in water), HPLC buffer B (100 mM hexafluoroisopropanol and 15 mM 
triethylamine in methanol), TEAA buffer (50% molar basis triethylamine, 50% molar basis 
glacial acetic acid, pH = 7.0), Cu-TBTA (10 mM Copper (II)-Tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine) in 55% dimethyl sulfoxide (DMSO), 45% water), 1X 
phosphate buffered saline (PBS) (137 mM sodium chloride, 2.7 mM potassium chloride, 
10 mM disodium phosphate, 1.8 mM monopotassium phosphate in water, pH = 7.4), and 
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1X TAE (40 mM tris(hydroxymethyl)aminomethane, 20 mM acetic acid, 1 mM 
ethylenediaminetetraacetic acid). 
3.3.2 Synthesis of ssDNA-Amphiphiles 
ssDNA sequences were purchased from Integrated DNA Technologies (Coralville, IA) 
with a 3’-amino modifier and an optional 5’ HEX (538/555 nm ex/em) or hexynyl (alkyne) 
group. The G-rich sequence (5’-CTCTTGGGGG-AmMo-3’) and C-rich sequence (5’-
CCCATTACCCTAGACCCTTATCCC-AmMo-3’) were used in this study. ssDNA was 
precipitated in water using 100 mM cetyl trimethylammonium bromide (CTAB) and 
centrifuged for 15 minutes at 16,100 g, followed by removal of the liquid and drying of the 
precipitate under an airstream to remove any excess water. The dried precipitated ssDNA 
was then resuspended in 90%/10% (v/v) mixture of dimethylformamide (DMF) and 
DMSO at 500 µM. The C16 dialkyl tail with the C12 hydrocarbon spacer was synthesized 
as described elsewhere,22 added in 10 times molar excess, and reacted for 16 h at 65 °C. 
The solution was concentrated by drying in a vacuum oven until approximately 50 µL in 
volume. The reaction product with the ssDNA-amphiphile and unreacted ssDNA was 
precipitated by a lithium perchlorate precipitation, where 1 mL of lithium perchlorate in 
acetone (2.5% w/v) was added and the solution was mixed until homogeneous, followed 
by the addition of 100 µL of water and placed in a -20 °C freezer for 15 min. The precipitate 
was centrifuged for 15 min at 16,100 g and rehydrated with 1 mL of water and filtered 
through a 0.45 µm PES filter (GE Healthcare, Chicago, IL). The filtered ssDNA-
amphiphiles were separated from unreacted ssDNA using HPLC with HPLC buffer A and 
HPLC buffer B over 30 min. ssDNA-amphiphiles were then dried under an air stream to 
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approximately 150 µL, precipitated with 1 mL of lithium perchlorate in acetone to remove 
HPLC buffer components, and rehydrated at 500 µM in water for storage at -20 °C. 
3.3.3 Alkyne DOTA-Thiol Reaction 
ssDNA-amphiphiles with a 5’-alkyne modification were mixed with ten molar equivalents 
of 1,4,7,10-tetraazacyclododecane-1,4,7-tris(acetic acid)-10-(2-thioethyl)acetamide 
(DOTA-thiol) and one tenth molar equivalent of 2-hydroxy-2-methylpropriophenone 
photoinitiator in water. The solution was degassed under vacuum for 15 min and stirred 
under UV light for 2 h. The solution was dialyzed overnight using a Tube-O-DIALYZER 
Medi 1K MWCO dialysis membrane (G-Biosciences, St. Louis, MO). DOTA-labeled 
ssDNA-amphiphiles were then concentrated to 500 µM by drying under an air stream. 
3.3.4 IRDye 800CW Click Reaction 
ssDNA-amphiphiles with a 5’-alkyne modification were mixed in 50% water and 50% 
DMSO to a final concentration of 100 µM. TEAA buffer was added to a concentration of 
200 mM, Cu-TBTA buffer was added to a concentration of 1 mM, ascorbic acid was added 
to a concentration of 2 mM, and IRDye 800CW Azide (778/794 nm ex/em) (Licor, Lincoln, 
NE) was added in five times molar excess of the ssDNA-amphiphiles. The solution was 
mixed and left overnight in the dark at room temperature, followed by a lithium perchlorate 
in acetone precipitation to remove excess buffer components. The dye-labeled ssDNA-
amphiphiles were rehydrated at 500 µM in water for storage at -20 °C. 
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3.3.5 Liquid Chromatography – Mass Spectrometry (LC-MS) 
ssDNA-amphiphiles were analyzed using an Agilent 1100 LC MSD Model G1946 Mass 
Spectrometer at the University of Minnesota Masonic Cancer Center. 4 µL of ssDNA-
amphiphiles at 500 µM were injected onto a 300 µm C3 column with a 20 min gradient 
between 15 mM ammonium acetate in water and acetonitrile. The eluent of the 
chromatography column was sent to the mass spectrometer to determine the mass of the 
ssDNA-amphiphiles. 
3.3.6 Nanotube Preparation 
ssDNA nanotubes containing different amphiphiles (unlabeled mixed with fluorescently-
labeled or DOTA-labeled) were created by combining the desired amphiphiles at the 
correct ratio in water. One volume equivalent of DMSO was added to the mixtures so the 
final DMSO concentration was 50% (v/v). The mixtures were then stirred for 4 h, during 
which water was slowly added to the mixtures until the final DMSO concentration at 4 h 
was 10% (v/v). Mixtures were dialyzed overnight using a Tube-O-DIALYZER Medi 1K 
MWCO dialysis membrane to remove excess DMSO and dried under an air stream to 500 
µM to prepare for nanoparticle separation. 
3.3.7 Nanotube Separation via Size Exclusion Chromatography 
Nanotubes were separated from micelles using size exclusion chromatography on an Äkta 
fast protein liquid chromatography (FPLC) (Amersham Biosciences, Piscataway, NJ). A 
C10/20 Column (GE Healthcare, Chicago, IL) loaded with Sepharose CL-4B 
chromatography matrix was used to separate the nanoparticles. 500 µM of ssDNA-
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amphiphile mixtures were loaded at 500 µL per run onto the column and separated using 
water as a buffer. Fractions were collected based on UV absorbance of the eluent, dried 
under an airstream to 500 µM, and analyzed using cryogenic transmission electron 
microscopy (cryo-TEM).  
3.3.8 Cryogenic Transmission Electron Microscopy 
Lacey Formvar/Carbon 200 mesh copper grids were purchased from Ted Pella (Redding, 
CA) and glow-discharged for 1 min to make the grids more hydrophilic. 4.5 µL of 500 µM 
ssDNA-amphiphiles in water were deposited onto the grid and vitrified in liquid ethane 
using a Vitrobot (Vitrobot parameters: 5 sec blot time, 3 sec wait time, 3 sec relax time, 0 
offset, 95% humidity, 25 °C). The grids were transferred to and kept under liquid nitrogen 
until imaged on a Tecnai G2 Spirit TWIN 20-120 kV/LaB6 TEM operated at an 
accelerating voltage of 120 kV using an Eagle 2k CCD camera at the University of 
Minnesota Characterization Facility. Size analysis of 31 micelles, and 153 nanotubes, and 
50 C-rich nanotubes was performed using ImageJ software. 
3.3.9 Cell Culture 
GL261 mouse glioblastoma cells (NIH) or C8-D1A healthy mouse astrocytes (ATCC, 
Manassas, VA) were cultured at 37 °C and 5% CO2 using Dulbecco’s Modified Eagle 
Medium (DMEM) (Thermo Fisher Scientific, Rockford, IL) supplemented with 10% (v/v) 
fetal bovine serum (FBS) (Thermo Fisher Scientific, Rockford, IL) and 100 units/mL 
penicillin, 0.1 mg/mL streptomycin. Cells were passaged when they reached 80% 
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confluence by treatment with TrypLE Express Cell dissociation agent (Thermo Fisher 
Scientific, Rockford, IL). 
3.3.10 Nanotube Serum Stability via Gel Electrophoresis 
Nanotubes containing 20 mol% HEX-labeled ssDNA-amphiphiles were prepared at 250 
µM in water on an amphiphile basis. Nanotubes were mixed into three separate conditions 
using 2.5 µL of nanotubes and 47.5 µL of solution, for 50 µL total volume of mixture and 
12.5 µM final ssDNA-amphiphile concentration. The three solutions used were: 5 µL of 
10X PBS with 42.5 µL water as a control, 5 µL 10X PBS with 5 µL FBS with 37.5 µL of 
water (10% v/v FBS) to mimic in vitro conditions, and 5 µL 10X PBS with 42.5 µL FBS 
(85% v/v FBS) to mimic in vivo conditions. Nanotube solutions were incubated at 37 °C 
for 24 h and were run on 2% agarose gels (2% agarose in 1X TAE buffer) at 120 V for 35 
min, and imaged using a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA).  
3.3.11 Nanotube Exonuclease/Endonuclease Stability via Gel Electrophoresis 
Nanotubes containing 20 mol% HEX-labeled ssDNA-amphiphiles were prepared at 250 
µM in water on an amphiphile basis. Nanotubes were mixed with DNase 1 and exonuclease 
III (Thermo Fisher Scientific, Rockford, IL) using 2.5 µL of nanotubes and 47.5 µL of 
solution for 50 µL total solution and 12.5 µM final ssDNA-amphiphile concentration. The 
47.5 µL solutions of nucleases contained 5 µL of the 10X reaction buffer provided by each 
kit to create a final concentration with the ssDNA-amphiphiles of 1X reaction buffer 
Nuclease concentrations were tested between 0 and 5 U/mL final concentration. Nanotube-
nuclease solutions were incubated at 37 °C for 24 h and were run on 2% agarose gels (2% 
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agarose in 1X TAE buffer) at 120 V for 35 min, and imaged using a ChemiDoc MP Imaging 
System (Bio-Rad, Hercules, CA).  
3.3.12 Nanoparticle Internalization via Confocal Microscopy and Organelle 
Colocalization 
ssDNA-amphiphile nanoparticles containing 20 mol% HEX-labeled ssDNA-amphiphiles 
were prepared at 250 µM in 1X PBS. 200,000 GL261 or C8-D1A cells were deposited onto 
glass coverslips within wells of a 24-well plate and allowed to adhere and proliferate for 
24 h. The next day, media was replaced with 500 µL of fresh media, and nanoparticles 
were added to a final concentration of 12.5 µM. After 24 h, the media containing 
nanoparticles was removed and the cells were washed once with 1X PBS.  The cells were 
then stained simultaneously for their nuclei and membranes using Hoechst 33342 (Thermo 
Fisher Scientific, Rockford, IL) at 0.92 µg/mL and Wheat Germ Agglutinin AlexaFluor647 
(Thermo Fisher Scientific, Rockford, IL) at 5.0 µg/mL respectively for 7 min at 37 °C. The 
cells were then washed once with 1X PBS and fixed using 4% paraformaldehyde in 1X 
PBS for 10 min at room temperature, and then washed twice with 1X PBS to remove any 
remaining paraformaldehyde. Cells were mounted onto glass slides using Prolong 
Diamond Antifade Mountant (Thermo Fisher Scientific, Rockford, IL) and imaged with an 
Olympus FluoView FV1000 BX2 Upright Confocal Microscope (University Imaging 
Centers, University of Minnesota). Image analysis was performed using ImageJ software.  
Organelle colocalization was performed in the same manner, but the media replenishment 
after 24 h used 1 mL instead of 500 µL. Early endosomes were stained by adding 10 µL of 
CellLight Early Endosomes-GFP Bacman 2.0 (Thermo Fisher Scientific, Rockford, IL) for 
78 
 
a final concentration of 10 particles per well. The CellLight solution was added at the same 
time as the HEX-labeled ssDNA-amphiphiles, which had a final concentration of 12.5 µM. 
2 h prior to the completion of the 24 h incubation, Lysotracker Deep Red (Thermo Fisher 
Scientific, Rockford, IL) was added to the wells at a final concentration of 200 nM. At the 
end of the 24 h incubation, the media containing nanoparticles was removed and the cells 
were washed once with 1X PBS. The nuclei were then stained using Hoechst 33342 at 0.92 
µg/mL for 10 min at 37 °C, washed once with 1X PBS, fixed with 4% paraformaldehyde 
in 1X PBS for 10 min at room temperature, washed twice with 1X PBS, and mounted onto 
glass slides using Prolong Diamond Antifade Mountant. The cells were then imaged with 
an Olympus FluoView FV1000 BX2 Upright Confocal Microscope, with image analysis 
performed in ImageJ software. 
3.3.13 Inhibition of Endocytosis 
GL261 cells were sub-cultured in a black 96-well plate at 10,000 cells/well in 150 µL of 
media. After 24 h, media was replenished with 150 µL of fresh media and then cells were 
incubated with 5 µg/mL filipin III, 2 µM rottlerin, 80 µM dynasore (Abcam, Cambridge, 
UK), or no inhibitor for 30 min. Nanotubes containing 20 mol% HEX-labeled ssDNA-
amphiphiles were added to the cells at a final concentration of 12.5 µM for 1 h. Cells were 
then washed twice with 1X PBS to remove any non-internalized nanotubes and the 
fluorescence of internalized nanotubes was measured at 535/555 nm (ex/em) using the 
area-scanning function of a Synergy H1 microplate reader (BioTek, Winooski, VT). 
Autofluorescence of untreated cells was subtracted from all fluorescence measurements. 
Comparisons between groups at a given time point were performed using an ANOVA 
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analysis with a post-hoc Tukey’s HSD test, while pair-wise t-tests were used for 
comparisons between the same inhibitor across time points. 
3.3.14 Direct Injections of Nanotubes to Orthotopic Glioblastoma Mouse Model 
Male C57BL/6J mice were purchased from Jackson Laboratory. Four mice were placed 
into deep anesthesia using an intraperitoneal injection of ketamine (100 mg/kg) and 
xylazine (10 mg/kg). Buprenorphine (0.03 mg/mL intramuscular) was administered, the 
mouse head was sterilized, and a 1 cm incision was made along the scalp. 30,000 GL261 
cells in 3 µL of sterile saline were implanted into the right-side striatum of the mice. 
Nanotubes containing 20 mol% IRDye 800CW-labeled ssDNA-amphiphiles were prepared 
at 1 mM on an amphiphile basis in 1X PBS. Three of the mice were anesthetized with 
ketamine (100 mg/kg) and xylazine (10 mg/kg) and 2 µL of the nanotube solution was 
injected into both the left and right striatum, 14 days after tumor cell implantation. At 45 
to 105 min after nanotube injections, mice were decapitated, and brains were taken and 
fixed in 4% paraformaldehyde overnight. Mouse brains were imaged using an In vivo 
Imaging System (IVIS) (University Imaging Centers, University of Minnesota) with 
780/820 nm excitation emission settings. 
3.3.15 Fluorescent Immunohistochemistry (IHC) Staining and Imaging of Brain Tissue 
Following direct imaging, the mouse brains were fixed in 4% paraformaldehyde in 1X 
PBS, dehydrated in 30% sucrose in 1X PBS, and embedded with cryo-compound OCT 
(Tissue-Tek, Sacura). The brains were then frozen at -80 °C, 10 µm sections were cut using 
a Leica cryostat, mounted onto charged Superfrost Plus glass slides (Fisher Scientific), and 
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stored at -20 °C until staining. The tissue sections were incubated with polyclonal 
antibodies against glial fibrillary acidic protein (GFAP) (Lifespan Biosciences, Seattle 
WA) diluted 1:500 in 1X PBS with 1% tween and 5% donkey serum in a humidified 
chamber at 4 °C overnight. The sections were then incubated with AlexaFluor-488 
secondary antibody diluted 1:750 (R&D Systems, Minneapolis MN) for 1 h at room 
temperature, followed by staining with DAPI for 10 min at room temperature. Mounted 
slices were imaged in three fluorescent channels using a Nikon Eclipse TE2000-U inverted 
wide-field fluorescent microscope (University Imaging Centers, University of Minnesota). 
Image analysis was performed using ImageJ software. 
3.3.16 Micro-Positron Emission Tomography (µPET)/Computerized Tomography (CT) 
Imaging of Orthotopic Glioblastoma Mouse Model 
Tumors were prepared in the same manner as for direct brain injections. Fourteen days 
after GL261 implantation, nanotubes containing 5 mol% DOTA-labeled ssDNA-
amphiphiles were mixed with 64CuCl2 (Department of Medical Physics, University of 
Wisconsin, WI). The dried 64CuCl2 salt was dissolved in 100 mM sodium acetate in water 
(pH = 6) at 2 µCi/µL. The nanotubes at 250 µM were diluted to 150 µM in 2X PBS and 
then mixed with the 64Cu solution (1:1 v/v) giving final concentrations of 75 µM ssDNA-
amphiphile and 1 µCi/µL 64Cu in 1X PBS. The mixture was incubated at 37 °C for 1 h to 
allow for chelation of the radioisotope by the DOTA moieties as well as to pre-heat the 
solution prior to injection.  
Mice were placed under a heat lamp prior to injections to dilate the veins in their tails. The 
tails were wiped with ethanol swabs to clean them prior to injection, and 200 µL of the 
81 
 
64Cu-labeled nanotube solution was injected into the lateral tail veins of the mice. The final 
solution injected contained approximately 0.8 pmol of 64Cu and 1.5 nmol of DOTA-labeled 
ssDNA-amphiphiles, approximately 1,850 times molar excess of DOTA to 64Cu, which has 
been shown to entirely chelate all available copper.93 The radioactivity and time of 
measurement for each individual syringe was measured immediately before and after tail 
vein injections. 15 min prior to each imaging time point (1, 3, 24 h after injection), mice 
were anesthetized using 3% isofluorane in oxygen at 0.8 L/min flow. μPET and CT scans 
were taken on a Siemens Inveon μPET/CT scanner (Center for Magnetic Resonance 
Research, University of Minnesota). After the 1 h imaging time point, mice were placed 
under a heat lamp until they regained consciousness. After either the 3 h or the 24 h time 
point, mice were euthanized for ex vivo organ radioactivity measurements; if mice were 
not euthanized after the 3 h time point, they were placed under a heat lamp until they 
regained consciousness. 
Images from the µPET/CT scans were saved as DICOM files and cropped to separate each 
individual mouse. This was done using a custom interactive tool written for MevisLab 
(http://www.mevislab.de). Care was taken to maintain the coordinate system and the 
calibrated radiological values contained in the original DICOM files. From these separated 
images, volumetric 3D renderings of each mouse were created for the whole mouse body. 
ImageJ was used to create the maximum intensity projections of the head of each mouse 
and to plot the µPET intensity profiles as a function of distance across the head of the 
mouse, starting from the left hemisphere. 
82 
 
All animal experiments in this chapter were approved by the IACUC at the University of 
Minnesota – Twin Cities. 
3.3.17 Ex Vivo Biodistribution Analysis 
At 3 h or 24 h after injections, mice were euthanized to collect organs for the biodistribution 
measurements. Organs were excised and weighed to determine their mass. The 
radioactivity of each organ (kilo counts per minute, kcpm) was recorded using a scintillator 
and converted to µCi using a calibration curve. The radiation values for each organ were 
then adjusted for the decay half-life of 64Cu (12.7 h). The total injected dose was calculated 
by measuring the decay-adjusted radiation in the syringe prior to the injection and 
subtracting the decay-adjusted radiation in the syringe after injection. Additionally, the 
decay-adjusted radiation in each mouse’s tail at the time of euthanasia was subtracted due 
to the possibility of missing the vein during injection, thereby limiting the amount of 64Cu 
systemically delivered. Organ radioactivity was scaled to the normalized injected dose and 
then scaled by the mass of the organ. Data were plotted as percent injected dose per gram 
of tissue (%ID/g) and statistically analysis between the two timepoints was performed with 
a student’s t-test.  
Images from the µPET/CT scans were saved as DICOM files and cropped to separate each 
individual mouse. This was done using a custom interactive tool written for MevisLab 
(http://www.mevislab.de). Care was taken to maintain the coordinate system and the 
calibrated radiological values contained in the original DICOM files. From these separated 
images, volumetric 3D renderings of each mouse were created for the whole mouse body. 
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ImageJ was used to create the maximum intensity projections of the head of each mouse 
and to plot the µPET intensity profiles as a function of distance across the head of the 
mouse, starting from the left hemisphere.  
3.4 Results 
3.4.1 Synthesis and Characterization of Nanoparticles 
Synthesis steps for all ssDNA-amphiphiles are shown in Figure 3.1 and 3.2. Successful 
synthesis was verified using LC-MS (Table 3.1).  
 
Figure 3.1 Synthesis schemes of ssDNA-amphiphiles with modifications pre-attached to the ssDNA. The 
inset shows the HEX modification. The full protocol for the first three steps is described elsewhere.22 
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Figure 3.2 Synthesis schemes of ssDNA-amphiphiles with modifications added to the ssDNA via alkyne 
reactions. The insets show the chemical structures of all modifications used. The full protocol for the first 
three reaction steps is described elsewhere.22 
Table 3.1 Expected and measured masses of ssDNA-amphiphiles that did not require addition modification 
at the 5` terminus. 
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Figure 3.3A shows the chemical structures of the different amphiphiles used in this work. 
Cryo-TEM was used to determine the size of the nanoparticles formed due to self-assembly 
in aqueous solution. The G-rich ssDNA-amphiphiles formed 10 ± 1 by 8 ± 1 nm weakly 
ellipsoidal micelles and nanotubes 153 ± 105 nm in length, 25 ± 2 nm in width, and had a 
wall thickness of 6 ± 1 nm.  
 
Figure 3.3 (A) Chemical structures of different ssDNA amphiphiles used to create self-assembled structures. 
(B) Cryo-TEM of ssDNA amphiphiles self-assembled into nanotubes (after FPLC separation), scale bar is 
100 nm. 
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We hypothesized that the nanotubes were formed when the hydrophobic amphiphile tails 
sequester together creating a bilayer while the ssDNA headgroups extend away from the 
hydrophobic tails towards the interior and exterior of the nanotubes. This structure is based 
on previous work using SAXS and cryo-TEM analysis that indicates a bilayer structure.23, 
24 Figure 3.3C shows a cryo-TEM image of the ssDNA-amphiphiles self-assembling into 
nanotubes. Nanotubes were separated from micelles using size exclusion chromatography. 
Although full separation of the two nanostructures was never possible due to overlapping 
elution peaks, it was possible to separate the majority of the nanotubes from the micelles 
for use as separate samples (Figure 3.4 shows cryo-TEM images of the nanotubes and 
micelles before and after separation). 
 
Figure 3.4 Cryo-TEM images of ssDNA amphiphiles (A) prior to FPLC showing presence of micelles and 
nanotubes, (B) micelle fraction after FPLC, and (C) nanotube fraction after FPLC. Scale bar is 100 nm in all 
images. 
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3.4.2 Serum and Nuclease Stability of Nanotubes 
The stability of nanotubes in different serum concentrations and nuclease concentrations 
was investigated using gel electrophoresis to evaluate degradation. The nanotubes were 
exposed to 1X PBS, 10% FBS (v/v) in 1X PBS to mimic in vitro serum conditions, and 
85% FBS (v/v) in 1X PBS to mimic in vivo serum conditions. As a control, each of the 
solutions was tested in the absence of the ssDNA-amphiphile nanotubes to ensure that all 
signal observed originated from the DNA nanoparticles. After 24 h incubations at 37 °C, it 
was found that there was little change in the electrophoretic mobility of the nanotubes when 
incubated with 10% FBS (Figure 3.5A). At 85% FBS concentration, the nanotubes showed 
significantly less electrophoretic mobility (Figure 3.5A). This is likely the result of 
adsorption of serum proteins onto the surface of the nanotubes, as this adsorption would 
cause a screening of the negative charges on the DNA backbone as well as an increase in 
the overall size of the nanoparticles, where both effects lead to less overall electrophoretic 
mobility.  
The G-rich nanotubes were also tested for their stability after exposure to varying 
concentrations of DNAse I and exonuclease III. After incubation with nuclease 
concentrations between 0 and 5 U/mL for 24 h at 37 °C, it was found that there was no 
degradation of the DNA nanotubes when exposed to either DNAse I (Figure 3.5B) or 
Exonuclease III (Figure 3.5C). The lack of any degradation of the nanotubes is promising 
for their in vivo use. 
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Figure 3.5 (A) Serum stability of nanotubes 20% labeled with HEX. (B, C) Nuclease stability of nanotubes 
with DNAse1 (B) or ExonucleaseIII (C) with concentrations varying between 0 U/mL and 5 U/mL.  
3.4.3 Nanotube and Micelle Cell Internalization 
Confocal microscopy was performed on GL261 mouse glioblastoma cells incubated for 24 
h at 37 °C with HEX-labeled nanotubes (Figure 3.6A) and micelles (Figure 3.6B) to 
determine the extent of internalization for each type of nanoparticle. The micelles showed 
minimal surface binding and internalization after 24 h incubation, while the nanotubes 
clearly showed strong internalization. As a healthy control cell line, C8-D1A healthy 
mouse astrocytes were also incubated with the nanotubes (Figure 3.6C) and micelles 
(Figure 3.6D) and showed no internalization with minimal extracellular surface binding.  
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Figure 3.6 Confocal Microscopy of ssDNA-amphiphiles delivered to cells for 24 h at 37 °C. DNA-
amphiphiles are shown in green, nuclei in gray, and cell membranes in red. (A) GL261 cells with nanotubes. 
(B) GL261 cells with micelles. (C) C8-D1A Healthy Mouse Astrocytes with nanotubes. (D) C8-D1A Healthy 
Mouse Astrocytes with micelles. Scale bars are 20 µm.  
To determine if the nanotube internalization observed was due to the particular G-rich 
sequence of the ssDNA used, GL261 cells were incubated for 24 h at 37 °C with cytosine-
rich nanotubes (Figure 3.7). The C-rich sequence produced nanotubes 167 ± 79 nm in 
length, 29 ± 3 nm in width and 7 ± 1 nm in wall thickness, a similar size and shape to the 
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G-rich sequence (Figure 3.8). These nanotubes showed strong internalization despite the 
different ssDNA sequence.  
 
Figure 3.7 Confocal Microscopy of C-rich nanotubes delivered to GL261 cells for 24 h at 37 °C. DNA-
amphiphiles are shown in green, nuclei in gray, and cell membranes in red. Scale bar is 20 µm. 
 
Figure 3.8 Cryo-TEM image of C-rich ssDNA nanotubes after FPLC separation. Scale bar is 100 nm. 
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3.4.4 Intracellular Trafficking of Nanotubes 
Different endocytosis pathways were blocked to investigate which pathways were utilized 
by the nanotubes (Figure 3.9). Three pathways known to be utilized in the endocytosis of 
nanoparticles were inhibited: caveolae-mediated endocytosis inhibited by filipin III, 
clathrin-mediated endocytosis inhibited by dynasore,175 and micropinocytosis inhibited by 
rottlerin. The concentrations of each inhibitor used were based on previous literature.175, 176  
To test the internalization of the nanotubes, GL261 cells were incubated with the three 
inhibitors and HEX-labeled nanotubes at either 1 h or 6 h. Filipin III incubation showed 
statistically lower amounts of internalization after a 1 h incubation with relative 
internalization of 67 ± 4% relative to the untreated control cells. Rottlerin and dynasore 
incubations did not show any statistical difference from the no-inhibitor control after a 1 h 
incubation, with relative internalization of 87 ± 10% and 84 ± 5% respectively. Incubation 
of the nanotubes with endocytosis inhibitors for 6 h showed statistically lowered 
internalization for all inhibitors when compared to the no-inhibitor control.  
Filipin III incubation showed a relative internalization of 74 ± 1%, rottlerin incubation 
showed a relative internalization of 71 ± 2%, and dynasore incubation showed a relative 
internalization of 79 ± 2%. The intracellular fate of the nanotubes was further determined 
by incubating GL261 cells with the nanotubes for 24 h and staining internal organelles. 
The results, shown in Figure 3.10, show that the nanotubes are colocalized with the early 
endosomes, the acidic organelles, and are located free in the cytosol, as indicated by the 
magenta, yellow, and red color observed in the images respectively. 
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Figure 3.9 Fluorescence of internalized nanotubes after incubation for 2h at 37 °C with different 
internalization inhibitors. Filipin III inhibits caveolae-mediated endocytosis, Rottlerin inhibits 
macropinocytosis, Dynasore inhibits clathrin-mediated endocytosis. Statistical analysis compares inhibitor 
internalization to the internalization observed without inhibitor at a given time-point. Error bars represent 
Standard Error of the measurements. * p<0.05, ** p<0.005. No statistical differences were observed between 
the same inhibitor at different time points.  
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Figure 3.10 GL261 cells were incubated with nanotubes for 24 hours and then stained for nuclei (gray), early 
endosomes (blue), acidic organelles (green), and nanotubes (red). Frames A, B, C, and D show slices 2, 3, 4, 
and 5 µm above the glass coverslip respectively. Scale bars are 20 µm. 
3.4.5 Direct Injections of Nanotubes to Orthotopic Glioblastoma Mouse Model 
After observing strong cell internalization of the nanotubes after incubation with GL261 
cells in vitro, the retention of nanotubes in a more clinically-applicable system was tested 
by directly injecting nanotubes into an orthotopic glioblastoma mouse model. GL261 
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tumors were grown in the right hemisphere of mouse brains and IRDye 800CW-labeled 
nanotubes were directly injected into both the tumor right hemisphere and healthy left 
hemisphere of the brain. The mice were euthanized at different time points, their brains 
were excised, and imaged for nearIR fluorescence (Figure 3.11). One mouse did not receive 
any nanotube injections as a control. The average ratio of signal between the tumor 
hemisphere and healthy hemisphere was 2.25, while all three mice that received injections 
showed signal a full order of magnitude larger than the control mouse (Table 3.2).  
 
Figure 3.11 Results of direct brain injections of IRDye 800CW-labeled nanotubes into mice bearing 
orthotopic GL261 tumors. The radiant efficiency of fluorescently-labeled nanotubes for each mouse shown 
with a heat map.  
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Table 3.2 Radiant efficiency values of each mouse brain for the left and right hemispheres measured ex vivo. 
Radiant Efficiency units are [photons/s]/[µW/cm2]. 
 
The excised brains were then sectioned and stained for nuclei and glial fibrillary acidic 
protein (GFAP) to verify that the observed differences in fluorescence between healthy and 
tumor hemispheres was a result of differential retention of the nanotubes by the two 
regions. Figure 3.12A and Figure 3.12B clearly show nanotubes in the tumor hemisphere 
of the brain, as shown by the bright red signal. The healthy hemisphere, in contrast, shows 
no retention of nanotubes despite receiving an equivalent volume of fluorescently-labeled 
nanotubes. The lack of nanotubes in the healthy hemisphere and the absence of 
fluorescence by the tumor itself was verified by imaging the control mouse brain that had 
received GL261 injection but no nanotubes, showing no fluorescent signal (Figure 3.12C). 
Additional imaging of other brain slices shows that this observation is consistent 
throughout all brain sections (Figure 3.13), indicating that only the tumor hemisphere 
retained the ssDNA-amphiphile nanotubes and that the signal observed in Figure 3.12 is 
not specific to the site of the nanotube injection. 
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Figure 3.12 Wide-field fluorescent microscopy of excised mouse brains with nuclei stained in blue, glial 
fibrillary acidic protein stained in green, IRDye800CW nanotubes shown in red. Both hemispheres received 
an injection of the fluorescently-labeled nanotubes. (A) Mouse 1 Slide 72. (B) Mouse 2 Slide 66. (C) Conrol 
Mouse Slide 50. Scale bar is 500 µm. 
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Figure 3.13 Wide-field fluorescent microscopy of different Mouse 1 brain slices showing only the Near-IR 
fluorescence channel. Nanotubes are bright red. (A) Slice 50 (B) Slice 60 (C) Slice 70 (D) Slice 80 (E) Slice 
90 (F) Slice 100. Scale bar is 500 µm. 
3.4.6 Biodistribution of Systemically Delivered Nanotubes in Orthotopic Glioblastoma 
Mouse Model 
DOTA-labeled nanotubes were used to chelate 64Cu. DOTA labeling has been shown to 
result in minimal changes to the size and surface charge of nanoparticles.177, 178 The DOTA-
labeled amphiphiles were present in approximately 1850 times molar excess of 64Cu, 
ensuring that all available copper was chelated by the nanotubes.93 Mice bearing orthotopic 
GL261 tumors on the right brain hemisphere were imaged with µPET/CT at 1, 3, and 24 h 
after systemic injections of the nanotubes through their lateral tail vein to investigate the 
localization of the nanotubes in the mice over time. Mice were euthanized at either 3 h or 
24 h to evaluate biodistribution. Excised organs were weighed and measured for 
radioactivity to create a biodistribution at each time point. The activity of each organ was 
adjusted for the half-life decay of 64Cu and expressed as percentage of injected dose per 
gram of tissue, shown in Figure 3.14.  
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Figure 3.14 Comparison of Ex Vivo Biodistribution of nanotubes systemically delivered to mice bearing 
GL261 orthotopic tumors at 3 h and 24 h after injection. Error bars show standard error of measurement, * 
P<0.05. 
Statistical differences between the decay-adjusted 3 h and 24 h measurements were 
observed for the muscle, stomach, pancreas, liver, and brain. Although the other measured 
organs were not statistically different, all organs follow a similar trend, where the measured 
radioactivity decreased between 3 h and 24 h. P-values for the organ comparisons are 
available in Table 3.3. Here we report the nanotube brain accumulation at 3 h as 1.1 ± 0.2 
%ID/g and at 24 h as 0.4 ± 0.1 %ID/g. The organ with the highest accumulation at both 
time points was the liver.  
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Table 3.3 P-values from Student’s T-test comparing the 3 h and 24 h accumulation of nanotubes after 
systemic delivery to mice bearing GL261 orthotopic tumors.  
 
Additionally, maximum-intensity projections of the heads of each mouse from the 
µPET/CT images are shown for the 1, 3, and 24 h time points in Figure 3.15. These images 
are tail-view projections, viewing the head of the mouse looking from the tail, through the 
head, and out through the nose of the mouse. Figure 3.15 suggests that for some of the 
mice, there may be preferential nanotube accumulation occurred in the right hemisphere of 
the brain, the hemisphere which received the GL261 cells. This can be seen in mouse 1 and 
mouse 3 in the 1 h and 3 h µPET/CT images. This is further supported by the µPET profile 
intensity plots in Figure 3.16, which show the radiation in the brain of each mouse relative 
to the left edge of the mouse cranium. Volumetric 3D reconstructions of the µPET/CT 
scans for the whole body of each mouse can be seen for each time point in Figure 3.17. 
100 
 
 
Figure 3.15 Tail-view maximum intensity projection of µPET/CT scans of mice heads at 1 h (top row), 3 h 
(middle row), and 24 h (bottom row) after injection. µPET intensity scale bar has units of µCi/mL. The 
intensity of the µPET signal has not been adjusted for the 12.7 h half-life of 64Cu. 
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Figure 3.16 µPET signal intensity as a function of distance from the left side of the brain from the head-view 
images in Figure 3.15. A) Mouse 1 (blue) and Mouse 3 (red) at 1 h (solid line) and 3 h (dashed line). B) 
Mouse 2 (green) and Mouse 4 (purple) at 1 h (solid line) and 3 h (dashed line). Radiation intensity values 
have not been adjusted for the half-life decay of 64Cu. 
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Figure 3.17 Full body volumetric 3D reconstruction of µPET/CT mice imaged at 1 h (top row), 3 h (middle 
row), and 24 h (bottom row) after systemic injection of 64Cu-radiolabeled nanotubes. The µPET intensity 
scalebar for all images has units of µCi/mL, and the intensity of the µPET signal has not been adjusted for 
the 12.7 h half-life of 64Cu. From left to right in each row is Mouse 1 through 4. 
3.5 Discussion 
In this work, we used ssDNA-amphiphiles that self-assembled into micelles and nanotubes. 
Characterization via cryo-TEM showed that the nanotubes were monodisperse in width 
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and wall thickness, with dimensions of 25 ± 2 nm and 6 ± 1 nm respectively, and had an 
average length of 153 ± 105 nm, while the micelles that formed from the same ssDNA-
amphiphiles were weakly ellipsoidal, with dimensions of 10 ± 1 by 8 ± 1 nm, matching the 
shape characteristics of previously reported ssDNA-amphiphile micelles.93, 135 The two 
distinct populations of nanoparticles could be separated using size exclusion 
chromatography, allowing for the investigation of shape and size on the uptake properties 
of nanoparticles formed from the same ssDNA-amphiphile.  
A common limitation of ssDNA-based nanoparticles is their stability when delivered in 
vivo. Any potential alteration of the nanotube structure due to interactions with serum 
proteins could greatly limit the ability of ssDNA-based nanoparticles to act as drug delivery 
vehicles, and degradation of the amphiphiles themselves would entirely preclude their use. 
The main degradation pathways as reported in the literature are through desorption of 
ssDNA by serum proteins, and degradation by nucleases, where direct cleavage of the 
strand at an internal site by endonucleases, or removal of nucleotides at the terminus by 
exonucleases is a possibility.179 The stability of the nanotubes was investigated after 
incubation with varying amounts of FBS. Using 10% FBS in 1X PBS to mimic in vitro 
culture conditions, the DNA nanotubes showed no change in electrophoretic mobility, 
suggesting no change to the nanotube structure (Figure 3.5A Lane 3). Using 85% FBS to 
mimic in vivo conditions, the nanotubes showed a decrease in their electrophoretic mobility 
(Figure 3.5A Lane 5). As electrophoretic mobility is an indicator of the size/charge ratio of 
a molecule, it is possible that the size of the nanotubes increased, the net charge decreased, 
or both occurred simultaneously. This suggests that the nanotubes have adsorbed serum 
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proteins onto their surface in the presence of 85% FBS. No degradation products were 
observed after incubation with any serum solution as indicated by the lack of distinct bands 
with higher mobility than the control sample. 
ssDNA has been shown to rapidly degrade when exogenously delivered,180 posing another 
challenge to its use as a drug delivery vehicle. Therefore, the stability of the nanotubes was 
investigated after 24 h incubation at 37 °C with DNAse I and Exonuclease III at 
concentrations ranging between 0-5 U/mL. Figure 3.5B and 3.5C show that no degradation 
was observed for either nuclease over the entire range of concentrations. The average 
activity of circulating DNase I in healthy human patients is approximately 0.25 U/mL, 
while the circulating activity of DNAse I in human cancer patients is 0.1 U/mL or less.181, 
182 Therefore, even at more than ten times physiologically relevant concentrations, the 
ssDNA-amphiphile nanotubes show no degradation. Little degradation is observed for the 
exonuclease III, as the 3’-terminus of the amphiphiles is conjugated to the dialkyl tail, 
preventing exonuclease III from binding to the amphiphile. Additionally, the high local 
concentration of the ssDNA headgroups in the self-assembled nanostructures likely 
prevents interaction with DNase I, preventing degradation by internal cleavage. We did not 
investigate degradation of the amphiphiles due to 5’ exonucleases, as it has been shown 
that 5’ exonucleases from serum do not play a significant role in DNA breakdown even 
when the 5’-terminus is exposed.179  
Confocal imaging was used to determine the extent of internalization or non-specific 
membrane association for nanoparticles delivered to GL261 cells. After 24 h incubation, 
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little internalization was observed for the micelles, which mainly showed low non-specific 
membrane association (Figure 3.6B), while strong internalization was observed for the 
nanotubes (Figure 3.6A). It is possible that the differences in uptake observed between 
micelles and nanotubes made up of the same amphiphiles is the result of an unintended 
targeting effect. It has been demonstrated that when targeting moieties are present, 
elongated nanoparticles see stronger internalization than spherical nanoparticles.71 The 
results of the confocal imaging match these results of the sequence induced targeting. 
Therefore, we searched the literature for receptors that could be targeted by the ssDNA-
amphiphiles unintentionally.  
Scavenger receptors have been identified as a class of membrane-bound receptors that are 
capable of binding to certain polyanionic macromolecules.183 Among these, poly-guanine 
repeat units, such as the sequence found in the G-rich ssDNA, bind to several types of 
scavenger receptors. However, poly-cytosine repeat units do not bind to these same types 
of scavenger receptors. Therefore, to test whether the strong internalization observed by 
the G-rich ssDNA nanotubes was due to unintended targeted via scavenger receptor uptake, 
a cytosine-rich ssDNA sequence was used to create nanotubes that would be delivered to 
the GL261 cells. This C-rich amphiphile was found to form nanotubes of similar 
dimensions to the G-rich amphiphile (Figure 3.8). The GL261 cells showed strong 
internalization of the C-rich nanotubes after 24 h incubation at 37 °C (Figure 3.7). This 
shows indirectly that the internalization observed by the G-rich nanotubes may not be a 
result of unintended targeting of scavenger receptors.  
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The observed uptake of the nanotubes could also be a result of the cell type. It has been 
shown that the uptake of elongated nanoparticles was dependent on cell type as well as the 
size and shape of the nanoparticles.72 To test if the internalization of nanotubes and lack of 
internalization of micelles was specific to neural cells in general, and not the GL261 cells, 
micelles and nanotubes were incubated with C8-D1A healthy mouse astrocytes (Figure 
3.6C and Figure 3.6D). These cells showed no internalization and minimal non-specific 
membrane association. Although this alone does not prove specificity of the nanotubes for 
GL261 cells, this shows promising results that nanotubes can be used as a drug carrier for 
delivery to glioblastoma tumors without internalization to healthy astrocytes that could 
result in off-targeting side effects.  
The strong internalization of negatively charged ssDNA nanotubes by the GL261 cells is 
somewhat surprising, as the negatively charged cell membrane should repel the nanotubes. 
It has been shown that cationic particles show much stronger internalization as compared 
to neutral or anionic particles184 and indeed most internalization and transfection agents for 
nucleic acids utilize free cations such as calcium phosphate, cationic polymers such as 
polyethylenimine, or cationic lipids such as lipofectamine. As the precise internalization 
pathways utilized by the ssDNA nanotubes were unknown, different endocytosis pathways 
were inhibited and ssDNA nanotube internalization with and without these inhibitors was 
measured via fluorescence at different time points. Three pathways were inhibited: 
clathrin-mediated endocytosis was inhibited by Dynasore,175 caveolae-mediated 
endocytosis was inhibited by filipin III, and micropinocytosis was inhibited by rottlerin. 
Figure 3.9 shows that after incubation for 1 h, only filipin III showed a decrease in nanotube 
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internalization. Therefore, at this short time interval, caveolae-mediated endocytosis is 
used by the ssDNA nanotubes. The other two inhibitors showed decreased internalization 
at 1 h, but neither inhibitor showed statistical differences when compared to ssDNA 
nanotubes incubated without an inhibitor. However, after 6 h incubations, all three 
inhibitors showed statistically significant decreases in the internalization of nanotubes. 
This shows that all three pathways are somewhat utilized in the internalization of ssDNA 
nanotubes. It should be noted that the actual internalization of ssDNA nanotubes at 6 h was 
higher than internalization at 1 h for all mixtures tested, as more time was allowed for the 
internalization of ssDNA nanotubes. Confocal microscopy imaging of GL261 cells 24 h 
after nanotube incubation (Figure 3.10) indicates that the nanotubes are colocalized with 
the early endosomes, the acidic organelles, and free in the cytosol.  
This observed uptake into the early endosomes, acidic organelles, and cytosol is consistent 
with literature reports. It was shown that DNA nanocubes are internalized by human 
cervical cancer cells in an endosomal type pathway.185 DNA tetrahedral nanostructures 
were shown to be internalized by human cervical cancer cells in a caveolin-dependent 
pathway, where these nanostructures were transported to the lysosomes when unmodified 
but could be functionalized with nuclear localization signals that allowed for their escape 
from the lysosomes.186 Additionally, similar DNA tetrahedral nanostructures were shown 
to partition within the cytoplasm of HEK cells at 6 h, 24 h, and 72 h after transfection.187     
Investigation of the in vivo fate of the nanotubes started with the direct injection of the 
nanotubes into the brains of mice bearing orthotopic GL261 tumors. Injections of 
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fluorescently-labeled nanotubes were given to both hemispheres of the brain to compare 
the retention of the nanotubes by healthy tissue and tumor tissue. Ex vivo fluorescent 
imaging of the mouse brains showed that side of the brain with the tumor had 
approximately 2.25 times higher fluorescence than the healthy tissue (Figure 3.11), 
indicating higher nanotube retention by the side of the brain with the tumor. The brains 
were then sectioned, stained, and imaged. Representative slices from two mice are shown 
in Figure 3.12, showing bright fluorescence of the nanotubes in the side of the brain with 
the tumor and complete lack of fluorescence in the healthy tissue. As both hemispheres 
received the same injection of fluorescently-labeled nanotubes, the complete absence of 
nanotube signal in the healthy tissue was somewhat surprise. To confirm that this was not 
an artifact of different injection sites, each brain was imaged for nanotube fluorescence 
throughout the entire length of the brain. Representative slices from one mouse (shown in 
Figure 3.13) show no fluorescence of the nanotubes in the healthy tissue, indicating that 
the nanotubes were not strongly retained by the tissue in the healthy hemisphere of the 
brain, while they were retained by the tissue in the tumor hemisphere of the brain.  
The biodistribution of the 64Cu-labeled nanotubes was determined after their systemic 
injection into mice bearing orthotopic GL261 tumors. Mice were imaged using a µPET/CT 
scanner at 1, 3, and 24 h after injection, and euthanized after 3 h or 24 h allowing for organ 
radioactivity to be evaluated. All organs measured showed a decrease in radioactivity 
between 3 h and 24 h. The organ with the highest delivery was the liver, consistent with 
the blood clearance profiles of many types of nanoparticles.51 Brain accumulation at 3 h 
was 1.1 ± 0.2 %ID/g, while brain accumulation at 24 h was 0.4 ± 0.1 %ID/g (Figure 3.14). 
109 
 
This is significantly higher than literature reports of PEG-co-PLGA (poly lactic-co-
glycolic acid) nanoparticles, which show complete lack of accumulation of the 
nanoparticles 24 h after systemic tail vein injections when either non-targeted or peptide-
targeted.188 Similarly, targeted polystyrene nanorods coated with anti-transferrin 
monoclonal antibodies also showed only 0.25 %ID/g accumulation 6 h after systemic 
injection.71 Doxorubicin bound to non-targeted polymeric nanoparticles was shown to 
accumulate in the brain at less than 0.8 %ID/g 8 h after injection, and only when those 
nanoparticles were coated in the non-ionic surfactant polysorbate 80. Without the 
surfactant coating, the nanoparticles showed no significant accumulation in the brain.189 
Although internalization of the nanotubes by the GL261 cells was not confirmed after 
systemic injection of the nanotubes, higher radiation was observed for some mice on the 
side of the brain that had the tumors (Figure 3.15). These images show, along with the 
profile intensity plots (Figure 3.16), that mouse 1 and mouse 3 had higher accumulation of 
the nanotubes in the hemisphere of the brain that had the tumor 1 h and 3 h after injection. 
Additionally, mouse 2 may have had higher accumulation of the nanotubes in the 
hemisphere of the brain that had the tumor 1 h and 3 h after injection, but no conclusion 
can be drawn for mouse 4. Taken together, this suggests that the nanotubes may accumulate 
more in the tumor hemisphere of the brain. This is consistent with literature reports that 
glioblastoma tumors can cause a leaky vasculature and disruption of the BBB, allowing for 
better overall nanoparticle accumulation in the tumor tissue.149-151  
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In conclusion, we have reported the development, characterization, in vitro delivery, and 
in vivo delivery of short nanotubes self-assembled from G-rich ssDNA-amphiphiles. These 
nanotubes are stable after exposure to both serum and nucleases, allowing for their 
potential use as a drug delivery vehicle. The nanotubes can internalize to GL261 mouse 
glioblastoma cells, while they do not internalize into healthy mouse astrocytes. 
Additionally, neither cell type showed internalization of the micelles, suggesting that shape 
may affect the internalization. This is consistent with literature reports that nanoparticles 
are most efficiently internalized when they are an intermediate size between 100 nm and 
10.190, 191 The nanotubes were shown to utilize all three major endocytosis pathways when 
internalizing to GL261 cells. Direct brain injections to mice bearing orthotopic tumors 
showed that the tumor tissue retained the nanotubes. The biodistribution of the nanotubes 
after systemic injection showed high brain accumulation of the nanotubes compared to 
literature reports of similar nanoparticles. Together, this demonstrates that ssDNA-
amphiphile nanotubes are a promising nanoparticle for the delivery of therapeutics to 
glioblastoma tumors. 
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4 In Vitro Delivery of Chemotherapeutics to 
Glioblastoma Multiforme via Self-Assembled ssDNA-
Amphiphile Nanotubes 
4.1 Summary 
Previous work has shown differential retention of self-assembled single stranded DNA 
(ssDNA)-amphiphile nanotubes into the tumor hemisphere of mice bearing orthotopic 
glioblastoma tumors.  In this work we hypothesized that these nanotubes could be used to 
deliver the chemotherapeutic doxorubicin (DOX) in vitro to specifically inhibit the growth 
of GL261 mouse glioblastoma cells. We formed nanotubes, loaded them with DOX, and 
purified them using size exclusion chromatography. Release profile tests showed that 
minimal DOX was released from the nanotubes over an extended period of time in solution. 
In vitro tests with glioblastoma cells showed that ssDNA nanotubes alone were nontoxic. 
When delivered together, DOX-ssDNA nanotubes showed enhanced killing of 
glioblastoma cells compared to free DOX, demonstrating promise as a chemotherapeutic 
delivery vehicle. 
4.2 Introduction 
Glioblastoma multiforme (GBM) is one of the most malignant types of primary brain 
tumors, with a median survival time of less than one year, and targeted treatment options 
have not improved survival times. A significant barrier to delivery of therapeutics to the 
brain is the inability for small molecules to cross the blood-brain barrier. However, 
glioblastoma tumors have been shown to increase the permeability of the blood-brain 
barrier (BBB),149-151 providing a potential pathway for drug delivery vehicle accumulation 
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in combination with the enhanced permeation and retention effect that aids general tumor 
targeting.2 The most common clinical treatment for GBM is to surgically resect as much 
tumor mass as possible, followed by treatment with radiotherapy and the chemotherapeutic 
temozolomide (TMZ).192 TMZ was approved for use by the FDA in 2005 following a Phase 
III clinical trial. This treatment method was shown to increase the median survival time by 
two months while showing minimal additional toxicity.192  
The chemotherapeutic doxorubicin (DOX) has also been used extensively to treat GBM in 
combination with many different delivery mechanisms. It has been shown that DOX 
conjugated into polysorbate-80-coated poly(butyl cyanoacrylate) nanoparticles (DOX-NP 
+ PS) does not cause mortality when delivered intravenously three times at concentrations 
below 2.5 mg/kg to either healthy rats or rats with intracranial glioblastoma tumors.193 
Further studies with the same nanoparticle system showed that the DOX-NP + PS 
formulation significantly increase the survival time of rats with intracranial glioblastoma 
tumors compared to all other tested groups when delivered intravenously, with significant 
differences observed when comparing free DOX and the nanoparticle-loaded DOX 
formulations.194 A similar system using intravenously injected DOX loaded into 
poly(lactic-co-glycolic acid) nanoparticles coated with poloxamer 188 showed effective 
delivery of DOX across the BBB of rats with orthotopic glioblastomas.195 
Stealth liposomal DOX formulations in combination with radiotherapy have also been used 
clinically, showing 7-13 times higher accumulation in primary and metastatic glioblastoma 
tumors compared to healthy brain tissue.196 Additionally, four out of ten patients showed 
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complete response two months following the end of chemo-radiotherapy.196 Peptide-
targeted liposomes in conjunction with high-intensity focused ultrasound have been used 
to intravenously deliver DOX to orthotopic glioblastomas in mice and compared with free 
DOX delivery. Survival time of mice treated with peptide-targeted liposomal DOX was 
increased by 44% compared to untreated control and by an additional 22% when followed 
by high-intensity focused ultrasound directed at the tumor site.197 DOX has also been 
approved by the FDA for treatment of several other types of cancer including bladder, 
breast, stomach, lung, ovarian, and thyroid cancers. We therefore selected DOX as a 
chemotherapeutic due to its flexibility in treatment for other types of cancer and its 
previous use in a wide variety of delivery vehicles.  
We have previously used self-assembled ssDNA-amphiphile nanotubes that are capable of 
internalizing into mouse glioblastoma cells (Chapter 3). These ssDNA nanotubes were 
shown to internalize into GL261 mouse glioblastoma cells in vitro, with minimal 
internalization to C8-D1A healthy mouse astrocytes, while no internalization was observed 
for ssDNA micelles for either cell type. When delivered directly to both hemispheres of 
the brains of mice with orthotopic glioblastoma tumors in the right-side striatum, the 
ssDNA nanotubes were only strongly retained in the region immediately around the tumor, 
with no observed retention in the healthy hemisphere. When delivered intravenously to 
mice bearing orthotopic glioblastoma tumors in the right-side striatum, the ssDNA 
nanotubes accumulated in the whole brain at 0.4 ± 0.1 % injected dose per gram of tissue 
24 h after injection. Additionally, we observed preferential uptake of the nanotubes into 
the tumor hemisphere of the brain 1 h and 3 h after injection for at least two of four mice 
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tested. We therefore hypothesized that these nanotubes could be used to deliver the 
chemotherapeutic DOX to glioblastoma cells in vitro. Additionally, based on previous 
work, we hypothesized that DOX delivered via ssDNA-nanotubes would have higher 
cytotoxicity as compared to free DOX.   
In this work, we loaded ssDNA nanotubes with DOX to assess their efficacy as vehicles 
for in vitro delivery to GL261 mouse glioblastoma cells. The ssDNA nanotubes are self-
assembled entirely from ssDNA-amphiphiles. The ssDNA used in this work is a 10 
nucleotide (nt) sequence (5` – CTCTTGGGGG – AmMo – 3`), that was synthesized as an 
amphiphile by conjugating its 3’ primary amine it to a dialkyl C16 tail with a C12 
hydrocarbon spacer through a solution-phase reaction (Figure 4.1). This 10nt ssDNA-
amphiphile has been shown to self-assemble into hollow nanotubes and spherical 
micelles.24 Cryogenic transmission electron microscopy (cryo-TEM) Images showed that 
the micelle diameters were 10 ± 1 nm in major axis and 8 ± 1 nm in minor axis, and the 
nanotubes had a wall thickness of approximately 6 ± 1 nm, a diameter of 25 ± 2 nm, and 
length of 153 ± 105 nm (Chapter 3). Size exclusion chromatography was used to separate 
the micelles from the nanotubes into distinct samples (Figure 3.4). 
4.3 Materials and Methods 
4.3.1 Materials 
All materials were purchased from Sigma Aldrich and used without further purification or 
modification unless otherwise stated. Buffers include 1X phosphate buffered saline (PBS) 
(137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM disodium phosphate, 1.8 
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mM monopotassium sulfate in water, pH = 7.4). All ssDNA was purchased from IDT 
(Integrated DNA Technologies, Coralville, IA). The ssDNA sequence used in this work 
was (5` – CTCTTGGGGG – AmMo – 3`). 
4.3.2 Synthesis of DNA-amphiphiles 
ssDNA-amphiphiles were synthesized as described elsewhere.93 Briefly, ssDNA was 
prepared at 500 µM in water. 100 mM cetyltrimethylammonium bromide was added in 1.2 
times molar excess on a nucleotide basis to precipitate all ssDNA. This solution was then 
dried to remove all water, resuspended at 500 mM in 90%/10% (v/v) mixture of dimethyl 
formamide (DMF) and dimethyl sulfoxide (DMSO). N-hydroxysuccinimide-activated tails 
synthesized as described elsewhere22 were added in 10 times molar excess and reacted for 
16 h  at 65 °C, reacting with the primary amine on the 3` end of the ssDNA. The organic 
solvent was then dried and removed via precipitation with lithium perchlorate dissolved in 
acetone (2.5% w/v). The solution was then rehydrated in water and filtered through a 0.45 
µm polyether sulfone filter. The ssDNA-amphiphiles were then separated from the 
unreacted ssDNA via high performance liquid chromatography, dried under an airstream 
until reaching 500 µM, and placed in a -20°C freezer for storage. Successful synthesis was 
previously verified using liquid chromatography – mass spectroscopy (Table 3.1). The 
entire reaction scheme can be seen in Figure 4.1. 
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Figure 4.1 Reaction scheme of the ssDNA amphiphiles used in this work. The protocol for the first three 
reaction steps is described elsewhere.22 
4.3.3 DOX – ssDNA-Amphiphile Mixing 
Doxorubicin-hydrogen chloride (DOX) dissolved in water at 1 mg/mL was combined on 
an equimolar basis with ssDNA-amphiphiles in water at 500 µM. DMSO was added to the 
solution until the final DMSO concentration was 50% (v/v). The solution was stirred for 2 
h. Over 4 additional h, water was slowly added until the final concentration was 90% water, 
10 % DMSO (v/v) at the end of the 4 h. The mixture was dialyzed overnight in a Tube-O-
DIALYZER Medi 1k MWCO dialysis membrane (G-Biosciences, St. Louis, MO) to 
remove the DMSO. 
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4.3.4 Nanotube Separation 
Nanotubes, either empty or mixed with DOX, were separated from micelles using size 
exclusion chromatography on an Äkta fast protein liquid chromatographer (FPLC) 
(Amersham Biosciences, Piscataway, NJ). A C10/20 Column (GE Healthcare, Chicago, 
IL) loaded with Sepharose CL-4B chromatography matrix was used to separate the 
nanoparticles. 500 µM ssDNA-amphiphile mixtures were loaded 500 µL per run onto the 
column and separated using distilled water as an mobile phase. Fractions were collected 
based on UV absorbance of the eluent and then dried under an airstream to 500 µM as 
measured by UV-Vis absorbance. 
4.3.5 UV-Vis Absorbance Concentration Measurements 
DNA concentration can be calculated through the absorbance of light at 260 nm. However, 
DOX also absorbs light at this wavelength. Therefore, the absorbance of mixtures of 
ssDNA and DOX was measured at both 260 nm and 488 nm, the maximum absorbance 
wavelengths for DNA and DOX respectively. The extinction coefficient of the ssDNA at 
260 nm was provided by IDT as 89300 cm-1M-1 and assumed to remain the same after the 
attachment of the hydrophobic tail. The extinction coefficient of the ssDNA at 488 nm was 
calculated by measuring the absorbance of a known amount of ssDNA at both 260 nm and 
488 nm, providing an extinction coefficient at 488 nm of 135 cm-1M-1. Several known 
concentrations of DOX were prepared by weighing out solid DOX and suspending in 
known volumes of distilled water. The absorbance for each DOX sample was measured at 
both 260 nm and 488 nm, allowing for the calculation of the extinction coefficients for 
DOX as 14715 cm-1M-1 and 10200 cm-1M-1, respectively. With all four extinction 
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coefficients and the absorbance measurements at both 260 nm and 488 nm, the 
concentration of ssDNA-amphiphiles and DOX was calculated by solving the two coupled 
linear equations: the absorbance observed at 260 nm and 488 nm, each due to the 
absorbance of ssDNA and DOX. It was assumed that the absorbance of the nanotubes and 
DOX was additive with no interacting terms. 
4.3.6 DOX – ssDNA Nanotube Release Profile 
DOX – ssDNA nanotube mixtures were diluted to 50 µg/mL of DOX in 1X PBS. The 
mixture was then placed in a Tube-O-DIALYZER Micro 1k MWCO dialysis membrane 
(G-Biosciences, St. Louis, MO) and dialyzed against 2 L of 1X PBS for 2 weeks. At several 
time points during the dialysis, 2 µL samples were taken out of the dialysis membrane and 
the absorbance at 260 nm and 488 nm was measured to determine the DOX concentration. 
After 7 days of dialysis, 20 µL of the sample was taken out of the dialysis membrane for 
cryo-TEM imaging. 
4.3.7 Cryogenic Transmission Electron Microscopy 
Lacey Formvar/Carbon 200 mesh copper grids were purchased from Ted Pella (Redding, 
CA) and glow-discharged for 1 min to make the grids more hydrophilic. Samples of 250 
µM DOX – ssDNA nanotubes prior to PBS dialysis were in distilled water, while samples 
taken 7 days after the start of dialysis were in 1X PBS and were at approximately 50 µM. 
4.5 µL of the samples were deposited onto the grid and vitrified in liquid ethane using a 
Vitrobot (Vitrobot parameters: 4 sec blot time, 3 sec wait time, 3 sec relax time, 0 offset, 
95% humidity, 25 °C). The grids were transferred to and kept under liquid nitrogen until 
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imaged on a Tecnai G2 Spirit TWIN 20-120 kV/LaB6 TEM operated at an accelerating 
voltage of 120 kV using an Eagle 2k CCD camera at the University of Minnesota 
Characterization Facility. Size analysis of 50 nanotubes from each formulation was 
performed using ImageJ software. 
4.3.8 Cell Culture 
GL261 mouse glioblastoma cells, originally from NIH, were cultured at 37 °C and 5% CO2 
using Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher Scientific, Rockford, 
IL) supplemented with 10% (v/v) fetal bovine serum (FBS) (Thermo Fisher Scientific, 
Rockford, IL) and 100 units/mL penicillin, 0.1 mg/mL streptomycin (Thermo Fisher 
Scientific, Rockford, IL). Cells were passaged when they reached 80% confluence by 
treatment with TrypLE Express Cell dissociation agent (Thermo Fisher Scientific, 
Rockford, IL). 
4.3.9 Cell Viability Assays 
The effect of free DOX, empty ssDNA nanotubes, and DOX – ssDNA nanotubes on cell 
viability was assessed using the Cell Titer Glo 2.0 Assay (Promega Corporation, Madison, 
WI). 10,000 GL261 were deposited into black 96-well tissue culture treated plates with 
100 µL of media and allowed to adhere for 24 h at 37 °C. The next day, media was removed, 
95 µL of new media was added and 5 µL of each test sample dissolved in distilled water 
was added so that each well received the same concentration of media.  
To measure nanotube toxicity, empty ssDNA nanotubes with final concentrations between 
0 and 8 µM were delivered to the cells. The empty nanotubes were incubated with cells for 
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24 h at 37 °C to give ample time for the nanotubes to influence cell viability. To test the 
efficacy of DOX – ssDNA nanotube mixtures compared to free DOX, four samples were 
delivered to plated cells: distilled water, empty nanotubes in distilled water (5 µM of 
ssDNA-amphiphile), free DOX in distilled water (5 µg/mL) and DOX – ssDNA nanotube 
mixtures in distilled water (5 µg/mL DOX, 5 µM ssDNA-amphiphile). The four samples 
were incubated with cells for 12 h at 37 °C. This was followed by a single wash with 1X 
PBS, replenishment with 100 µL of media, and additional incubation at 37 °C for 36 h. 
Following the incubation with each of the four formulations, the cells were taken out of the 
37 °C incubator and allowed to equilibrate to room temperature, while the Cell Titer Glo 
2.0 solution was placed in a room temperature water bath. 100 µL of the Cell Titer Glo 2.0 
solution was added to each well of cells simultaneously and the entire plate was placed on 
an orbital shaker for 2 min and then allowed to rest for 10 min. The luminescence signal 
of each well was measured, and the luminescence of each group was normalized to the 
luminescence of the untreated cells. All results were compared using an ANOVA with a 
post-hoc Tukey’s HSD test.  
4.4 Results and Discussion 
4.4.1 DOX – DNA Nanotube Release Profile 
The retention of DOX by the nanotubes was investigated by dialyzing a sample of the DOX 
– ssDNA Nanotube mixture against 1X PBS for 2 weeks. 1X PBS was used as a dialysis 
medium, both inside and outside the dialysis membrane, because it closely mimics the salt 
concentration of cell media and serum. As shown in Figure 4.2, DOX was slow to release 
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from the dialysis membrane over the course of 2 weeks, with 88 ± 3 % retention of DOX 
over 1 week and 80 ± 5 % retention of DOX over 2 weeks.  
 
Figure 4.2 Release Profile of DOX – ssDNA nanotubes over time as a percentage of the starting 
concentration. Reported as average ± standard error of N=2 measurements. 
Because DOX acts as a chemotherapeutic by intercalating into the DNA double-helix, 
thereby preventing DNA replication,86-89 it was hypothesized that the DOX may bind to 
the ssDNA-amphiphiles in the nanotube structure, thus making its release in solution slow. 
Any DOX not associated with the ssDNA-amphiphiles should have quickly diffused out 
of the membrane, as DOX has a molecular weight of 543.52 Da, is water soluble, and the 
dialysis membrane used had a 1 kDa molecular weight cut-off. Therefore, this graph 
suggests that the release of DOX from the nanotubes is minimal in PBS solution on the 
timescales used for chemotherapeutic delivery. However, this experiment is not capable of 
capturing the complexity of the cellular environment, as it has been shown that 
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nanoparticles that do no degrade in solution will degrade and release their payload when 
exposed to the cellular environment.198 
4.4.2 Evolution of Nanotube Structure 
Seven days after the start of the PBS dialysis, a small sample of the nanotubes was taken 
for cryogenic transmission electron microscopy (cryo-TEM) imaging. This sample, shown 
in Figure 4.3, indicates that there is little to no change in the structure of the nanotubes over 
1 week. The size of the nanotubes is shown in Table 4.1.  
 
Figure 4.3 TEM image of DOX – ssDNA nanotube mixture after 7 days of dialysis in 1X PBS. Circled in 
black is surface water ice. Scale bars is 100 nm. 
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Table 4.1 Size characterization of DOX – ssDNA nanotubes before the start of dialysis and after 7 days of 
dialysis against 1X PBS. 50 nanotubes from cryo-TEM images of each sample were analyzed using ImageJ 
software. 
 
We observe no change in the diameter or wall thickness of the nanotubes over the first 
seven days of dialysis, but there does seem to be a slight increase in the length of the 
nanotubes over this period. Box plots for each measurement are shown in Figure 4.4. The 
width and wall thickness of these nanotubes is slightly higher than we previously reported 
for the nanotubes on their own (Chapter 3), but within statistical error.  
The length of these nanotubes in the presence of DOX is significantly longer than we 
previously reported for empty nanotubes. However, because the median length of both the 
pre-dialysis DOX – ssDNA nanotube sample and the 7-day dialysis DOX – ssDNA 
nanotube sample is smaller than the average of the sample, as shown in Figure 4.4, the 
distribution of lengths is not truly gaussian and is instead skewed to shorter lengths. It is 
unclear why the incorporated DOX affects the length of the nanotubes. Slight differences 
in preparation protocol, such as the mixing of with dimethyl sulfoxide and the subsequent 
dialysis, may cause differences in the assembly mechanism. It is also possible that the 
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incorporation of DOX affects the intermolecular forces of both the hydrophobic tail and 
the ssDNA headgroup, leading to changes in the assembled structure. 
 
Figure 4.4 Box plots of DOX – ssDNA nanotubes dimensions as measured by Cryo-TEM imaging before 
dialysis and after 7 days of dialysis in 1X PBS. (A) Distribution of lengths. (B) Distribution of diameters. (C) 
Distribution of wall thicknesses. 
4.4.3 Cytotoxicity of Unloaded Nanotubes 
The effect of empty DNA nanotubes on the viability of the GL261 mouse glioblastoma 
cells after incubation of the nanotubes with the cells for 24 h was also assessed. For all 
concentrations of ssDNA nanotubes between 0.25 and 8 µM, there was no significant 
decrease in cell viability compared to the untreated control (Figure 4.5). Additionally, no 
statistical differences were observed between any given pair of concentrations, where 
significance was assessed using ANOVA with a post-hoc Tukey’s HSD test and P-values 
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are shown in Table 4.2. This result is not surprising, as the ssDNA nanotubes are composed 
of an effectively random sequence of DNA.24  
 
Figure 4.5 Cell Viability of GL261 cells incubated for 24 hours with ssDNA nanotubes compared to untreated 
control. Error bars show standard error. N=3, measured in triplicate. 
Table 4.2 Pairwise P-Value comparisons between ssDNA nanotube concentrations using an ANOVA and 
post-hoc Tukey’s HSD test. 
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4.4.4 Efficacy of DOX – DNA Nanotube Mixtures 
In this work, we have chosen to use 5 µg/mL as the final DOX concentration for cell 
viability assays. Most cancer cells have IC50 values of less than 0.2 µM (0.11 µg/mL) 199, 
200. However, some GBM cell lines have IC50 values exceeding 20 µM (10.8 µg/mL) 200. 
Therefore, to ensure an appropriate response to DOX delivery would be observed for the 
GL261 cells, DOX was delivered at 5 µg/mL (9.2 µM). The efficacy of DOX – ssDNA 
nanotube mixtures was assessed by comparing the cell viability of GL261 glioblastoma 
cells when incubated with a control solution, empty ssDNA nanotubes, free DOX, and the 
DOX – ssDNA Nanotubes. The results of this experiment are shown in Figure 4.6. P-values 
from an ANOVA with post-hoc Tukey’s HSD test are shown in Table 4.3 comparing the 
GL261 cell response to different treatments. The empty ssDNA nanotubes were shown to 
have no effect on cell viability, consistent with the results from Figure 4.5. However, there 
is a significant improvement between free DOX and DOX – ssDNA nanotubes for the 
GL261 cell viability. This suggests that the nanotubes are more effective in the delivery of 
DOX than free DOX on its own, a promising result for the use of these nanotubes as a 
delivery vehicle.  
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Figure 4.6 Cell Viability of GL261 cells incubated for 12 hours with ssDNA nanotubes (5 µM), Free DOX 
(5 µg/mL), or DOX – ssDNA nanotubes (5 µM ssDNA nanotubes + 5 µg/mL DOX). Error bars show standard 
error. N=3, measured in triplicate. 
Table 4.3 P-values from ANOVA with post-hoc Tukey’s HSD test comparing GL261 cell response to 
different treatments. 
 
4.5 Conclusions 
In this report, we have demonstrated that ssDNA nanotubes can associate with DOX to act 
as a chemotherapeutic delivery vehicle. The presence of DOX increases the length of the 
nanotubes but does not change their diameter or wall thickness. When incubated in 1X PBS 
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for 2 weeks, some of the DOX is released by the nanotube structure, with 88 ± 3 % retention 
of DOX over 1 week and 80 ± 5 % retention of DOX over 2 weeks. We have shown that 
the incorporation of DOX into the ssDNA nanotube structure significantly improves the 
therapeutic effect when delivered to glioblastoma cells in vitro compared to the delivery of 
free DOX. We believe this makes the nanotubes a promising delivery vehicle for 
chemotherapy applications, as a larger percentage of cancer cells can be killed for a given 
drug dosage.  
Further studies need to be performed to investigate several aspects of this delivery 
mechanism. First the effect of DOX on the length of the ssDNA nanotubes should be 
investigated further. Additionally, the DOX : DNA nanotube ratio on cell viability must be 
investigated. It is possible that the ratio used in this work may not be the most effective 
ratio for achieving cell death. Additionally, the side-effects of off-targeting must be 
investigated. This should consist of both in vitro testing of the DOX – ssDNA nanotube 
mixture when delivered to healthy astrocyte cells, but the most reliable method for 
assessing the side-effects of this therapeutic – nanoparticle delivery will be through 
delivery to a mouse glioblastoma model, whereby tumor size can be tracked alongside 
animal weight, response times, and histological staining of other tissues, all of which can 
indicate the presence of healthy tissue damage due to off-targeting.  
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5 Conclusion 
Targeted delivery is an extremely promising contribution to the field of medicine. The 
design of novel targeting molecules and mechanisms has led to improved drug delivery in 
many disease types. The use of DNA in targeted delivery is a relatively novel concept. 
DNA nanotechnology as a field has existed for some time, with creations such as DNA 
origami and DNA tile assembly.168, 201 However, the use of ssDNA-amphiphiles for 
targeted delivery has not been widely reported. This thesis describes how ssDNA-
amphiphiles and their self-assembled structures can be used as targeted drug delivery 
vehicles. 
The direct targeting capability of ssDNA-amphiphile micelles was investigated by using a 
DNA aptamer sequence as the headgroup of the ssDNA-amphiphile. As PEGylation of 
nanoparticles can be important in prolonging the blood circulation lifetime when delivered 
intravenously, the effect of PEGylation on binding was investigated. Although the 
inclusion of a PEG corona on the micelles decreased binding with the target protein, the 
effect was not entirely lost, as the micelles were still able to bind significantly more to the 
target cells than to a control cell line. We showed that the targeted aptamer-amphiphile 
micelles were able to internalize into cancer cells expressing the aptamer target and were 
localized in the cytosol after 24 hours. At the same time, there was no internalization of the 
aptamer-amphiphile micelles to cells that did not express the aptamer target. In vivo studies 
showed that targeted and non-targeted ssDNA-amphiphile micelles accumulate in the 
tumor tissue at equal levels. However, only the targeted micelles that use the aptamer 
ssDNA sequence are capable of internalizing into the tumor cells. The non-targeted 
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micelles were only present in the extracellular space of the tumor tissue. Together, this 
shows that the targeted micelle system requires that the target molecule be present at the 
cell surface and that the targeting aptamer must be present for internalization.  
The passive targeting of cancer cells based on nanoparticle shape and size was investigated 
using ssDNA-amphiphile nanotubes. It has been shown in the literature that cells have 
preferential internalization of nanoparticles of different sizes and aspect ratios. We 
therefore used the ssDNA-amphiphile nanotubes, which self-assemble from ssDNA-
amphiphiles due to the sequence of ssDNA used and the types of lipid tails used, to target 
glioblastoma multiform. These nanotubes were shown to have preferential internalization 
to glioblastoma multiform cells and no internalization, with only minimal surface binding, 
to healthy astrocytes. Additionally, they are able to localize in the cytosol 24 h after 
internalization. When delivered directly to the brains of mice bearing glioblastoma tumors 
in only one hemisphere, the nanotubes showed retention in the tumor hemisphere, with 
minimal binding in the healthy tissue. This observation was conserved when delivered 
systemically. Additionally, the brain accumulation of the nanotubes was approximately 
0.40% injected dose per gram of tissue 24 hours after systemic injections, significantly 
higher than reported literature for other non-targeted nanoparticles.  
Following the promising results of nanotubes showing high brain accumulation in 
orthotopic glioblastoma mouse models, initial in vitro chemotherapy studies were 
performed using the same ssDNA-amphiphile nanotubes. The DOX – ssDNA nanotube 
mixtures showed slow release of the chemotherapeutic over the course of two weeks, 
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indicating that DOX bound directly to the nanotube structure. Additionally, cryo-TEM 
imaging showed no significant changes in the DOX – ssDNA nanotube structure over the 
same period. The nanotubes were shown to have no impact on cell viability when delivered 
on their own. However, when delivered mixed with DOX, the nanotubes showed increased 
cell death for the glioblastoma cells as compared to free DOX. Together, this is a promising 
result for the future uses of ssDNA nanotubes as a drug delivery vehicle. 
A follow-up project for this thesis would include the in vivo investigation of 
chemotherapeutic delivery by the ssDNA-amphiphile nanotubes. The promising in vivo 
biodistribution results and the in vitro chemotherapeutic efficacy results indicate that these 
ssDNA nanotubes may be able to significantly prolong the lives of animals compared to 
free doxorubicin delivery. Overall, the flexibility of ssDNA sequences and amphiphile 
structures show huge promise in the improvement of targeted drug delivery vehicles, 
through both active and passive targeting. 
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